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ABSTRACT 
REGULATION OF MTORC1 BY HOMOCYSTEINE AND ITS EFFECTS ON 




The molecular mechanisms leading to and responsible for age-related, sporadic 
Alzheimer’s disease (AD) remain largely unknown. It is well documented that aging 
patients with elevated levels of the amino acid metabolite homocysteine (Hcy) are 
at high risk of developing AD. The impact of Hcy on molecular clearance pathways 
in mammalian cells, including in-vitro cultured induced pluripotent stem cell-
derived forebrain neurons and in-vivo neurons in mouse brains is investigated in 
this research project. Exposure to high Hcy levels results in up-regulation of the 
mechanistic target of rapamycin complex 1 (mTORC1) activity, one of the major 
kinases in cells that is tightly linked to anabolic and catabolic pathways. Moreover, 
Hcy-mediated mTORC1 activity is only specific to Hcy and not to Hcy metabolites 
such as Hcy-thiolactone and cysteine. Homocysteine is sensed by a constitutive 
protein complex composed of leucyl-tRNA-synthetase (LeuRS) and folliculin 
(Flcn), which regulates mTOR tethering to lysosomal membranes. In hyper-
homocysteinemic human cells and cystathionine β-synthase-deficient mouse 
brains, an acute and chronic inhibition of autophagy, the molecular clearance 
pathway is detected. In Hcy-treated cells, mTORC1 mediates phosphorylation of 
ULK1 which consequently reduces LC3 lipidation. mTORC1 also dampens TFEB-
driven transcription of autophagy-related genes resulting in a buildup of abnormal 
proteins, including β-amyloid and phospho-Tau. Formation of these protein 
aggregates leads to AD-like neurodegeneration. This pathology can be prevented 
by inhibition of mTORC1 or by induction of autophagy, through TAT-Beclin1 
treatments. Here it is discussed that an increase of intracellular Hcy levels 
predisposes neurons to develop abnormal protein aggregates, which are 
hallmarks of AD and its associated onset and pathophysiology with age. 
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 CHAPTER 1 
INTRODUCTION AND BACKGROUND 
 
1.1 mTOR is a Major Integrator of Signaling Pathways in the Cell 
As a serine-threonine kinase and a member of phosphoinositide-3-kinase (PI3K) 
related kinase family, the mechanistic target of rapamycin (mTOR) is a central 
hub for various anabolic and catabolic pathways in the cell (Laplante and 
Sabatini 2012; Wullschleger, Loewith, and Hall 2006; Loewith and Hall 2011). 
Both synthetic pathways such as protein and lipid production as well as break-
down processes such as autophagy are influenced by mTOR activity (Laplante 
and Sabatini 2012) (Figure 1.1). Being observed along with other components in 
two different complexes, mTOR is the catalytic subunit in both mTORC1 and C2. 
Nutrient and growth factor signaling are mainly attributed to mTORC1 while 
cytoskeleton regulation, cell growth, and death are known to be controlled by 
mTORC2 (Laplante and Sabatini 2012; Guertin et al. 2006; Sarbassov et al. 
2004).   
 
1.2 mTORC1 and Amino Acid Signaling 
Mechanistic target of rapamycin complex 1 has been identified in two different 
states, either active or inactive. mTORC1 exists in diffused form throughout the 




Figure 1.1 Cellular signaling regulates mTORC1 activity through the TSC 
complex. The TSC complex represents a hub for incoming cellular signals 
ranging from hypoxia, DNA damage, and energy levels to growth factors, Wnt, 
and TNF signals. Signaling mediators and/or kinases modulate the GAP activity 
of the TSC complex to inhibit or activate Rheb. An inactive TSC complex results 
in activation of mTORC1 thereby promoting protein and lipid synthesis, energy 
metabolism, and inhibition of lysosomal biogenesis and autophagy. 
Source: Khayati, K., Nnah, I. C., and Dobrowolski, R., 2015. “Cellular Metabolism and 
Lysosomal mTOR Signaling.” Cell Death in Therapy, 11-22. 
 
active kinase along with other lysosomal membrane proteins which form the 
lysosome nutrient sensing (LYNUS) machinery (Settembre et al. 2013). LYNUS 
machinery is comprised of Rags (small GTPases in form of heterodimer) which 
act as docking sites for mTORC1 to tether on the lysosomal surface (Sancak et 
al. 2010), v-ATPase, a proton pump that acidifies the lysosomal lumen and plays 
prominent role in sensing amino acids availability inside the lysosome (Ohkuma 
1982), Ragulator, a guanine nucleotide exchange factor (GEF) for Rag A and B 
3 
 
GTPases (Sancak et al. 2010; Huang and Fingar 2014) and finally endosomal 
ATP-sensitive sodium ion-permeable channel which responds to ATP levels and 
regulates lysosomal membrane potential and pH stability (Cang et al. 2013). The 
reason for mTORC1 translocation on the lysosomal membrane as part of the 
LYNUS machinery is for being in close proximity with its activator, Ras homolog 
enriched in brain (Rheb) which is known as a small GTPase residing on the 
lysosomal membrane (Inoki et al. 2003; Tee et al. 2003). This mTORC1 
recruitment to lysosomal membrane largely depends on the availability of amino 
acids which are sensed by the LYNUS machinery, a process that is critical for 
mTORC1 to be able to regulate its downstream pathways (Sancak et al. 2010). 
This way, amino acids regulate mTORC1 activity by regulating its proximity to 
Rheb. So, amino acids are not only considered as building blocks of proteins but 
also play important roles in the maintenance of cellular homeostasis through 
activation of mTORC1 (Laplante and Sabatini 2012); among them, leucine (Leu) 
is known as the most potent one in regards to mTORC1 activation (Bar-peled 
and Sabatini 2014). 
   
1.3 Inside-Out Mechanism of Amino Acid Signaling through v-ATPase 
Vacuolar 𝐻+- adenosine triphosphatase (v-ATPase) is known as a proton pump 
which acidifies lysosomal lumen by hydrolyzing ATP and production of a proton 
gradient. This proton gradient is usually coupled with symport/antiport 
mechanism of amino acid transporters (Russnak, Konczal, and Mcintire 2001). V-
ATPase consists of V0 and V1 domains. V1, the cytoplasmic domain is 
4 
 
responsible for ATP hydrolysis that induces a conformational change in the 
integral membrane domain, V0. This integrated action of both domains promotes 
influx of protons across the endolysosomal membrane (Forgac 2007). In addition 
to its prominent role in vacuolar pH maintenance, v-ATPase is the main factor in 
sensing amino acid availability in the lysosome in order to regulate mTORC1 
activity (Zoncu 2011). By inhibiting the expression of genes encoding for v-
ATPase components and assessing mTORC1 activity, Zoncu et al. showed a 
strict dependence of mTORC1 on v-ATPase function. Furthermore, cells treated 
with Concanamycin A, a v-ATPase inhibitor, failed to recruit mTORC1 to their 
lysosomal membranes even in presence of amino acids. Therefore, it was 
proposed that upon amino acid availability, v-ATPase relays the signal to 
Ragulator, the Rag A/B activator, through which active Rags are bound on 
lysosomal surface which further facilitate tethering of mTORC1 to the complex 
(Zoncu 2011). Later, Stransky and Forgac showed that amino acid availability 
influences v-ATPase assembly and function as well, which in turn is crucial for 
culmination in mTORC1 activity (Stransky et al. 2015).    
     
1.4 Amino Acids can be Sensed and Edited through Interaction with 
Aminoacyl-tRNA Synthetases in the Cytoplasm 
 
Aminoacyl-tRNA synthetases (AARS) are enzymes generally known to facilitate 
binding of amino acids to their cognate tRNA (Serre et al. 2001). The so-called 
tRNA charging with amino acids is a two-step process consisting of binding of 
amino acid to AARS and being transferred to their cognate tRNAs; the later step 
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is called tRNA aminoacylation (Giegé 2008). During tRNA charging, amino acid-
bound AARS conjugates with AMP (an intermediate with high energy level) which 
later favors a high-energy ester bond formation between an amino acid and 3’-
terminal of the tRNA (Jakubowski 2012). Among AARSs, leucyl-tRNA synthetase 
(LeuRS) is the enzyme that promotes the transfer of Leu to its counterpart tRNA 
and is proposed to act as an important player in protein translation as well as 
being an mTORC1 activator by sensing available Leu in the cytoplasm (Han et 
al. 2012). 
In addition to their regular function in amino acid selectivity for tRNAs, 
AARSs are found to be able to edit non-proteinogenic amino acids such as 
homocysteine (Hcy). Inaccurate amino acids need to be edited in order to inhibit 
their incorporation into our proteins. Among AARSs, isoleucyl-tRNA synthetase 
(IleRS), valyl-tRNA synthetase (ValRS), lysyl-tRNA synthetase (LysRS) and 
LeuRS are known to edit Hcy (Jakubowski 2011). In general, amino acid editing 
by AARSs takes place in two ways: pre-transfer editing (edition of amino acids 
while they are bound to AARSs prior to tRNA binding) and post-transfer editing 
(amino acid editing after transfer to tRNAs) (Cvetesic, Perona, and Gruic-sovulj 
2012).  
Weak interaction between the side chain of the amino acid, which is 
recognized by an AARS, and the active site of the enzyme triggers editing 
process of non-proteinogenic amino acids. In the case of methionyl-tRNA 
synthetase (MetRS), amino acid charging and editing happen at the same active 
site of the enzyme which recognizes both methionine (Met) and Hcy. Methionine 
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binding to MetRS induces rearrangement in the active site of the enzyme through 
which aminoacylation is triggered, while Hcy fails to induce such rearrangements 
(Serre et al. 2001). 
In general, in process of editing, an amino acid conjugated with AMP or t-
RNA, undergoes hydrolysis reaction which gives rise to the production of a free 
amino acid. But if amino acid has a nucleophile group such as γSH in Hcy, it will 
be converted to a cyclized form of amino acid (thiolactone in the case of Hcy) 
(Lincecum et al. 2003). Homocysteine-thiolactone formation through MetRS is 
highly conserved in bacteria, yeasts, plants and humans and prone to 
aggregation and excretion in urine because of the low dissociation constant (pK = 
6.65) of its amino group (Jakubowski 2011). Methionyl-tRNA synthetase has a 
thiol-binding sub-site through which editing of Hcy occurs. There is competition 
between the side chain of amino acid and tRNA in binding to the carboxyl group 
of amino acid. Methyl group of Met binds firmly to specificity sub-site of MetRS 
through hydrophobic and hydrogen bonds, renders its carboxyl group free to bind 
to tRNA; while thiol group of Hcy is deficient in binding to specificity sub-site of 
MetRS, though wins the competition over tRNA in binding to carboxyl group of 
Hcy and produces cyclized Hcy-thiolactone (Serre et al. 2001). It is noteworthy 
that Hcy-thiolactone is very reactive and prone to damage protein structures by 
binding to amine groups of lysines incorporated into proteins leading to the 
formation of N-Hcy-proteins (Jakubowski, Boers, and Strauss 2008). Two 
enzymes which specifically hydrolyze Hcy-thiolactone back to Hcy, are bleomycin 
hydrolase (Blmh) and paraoxonase1 (Pon1). Bleomycin hydrolase-deficient mice 
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exert 1.8 fold more Hcy-thiolactone in their urine as compared to normal mice 
(Borowczyk, Tison, and Jakubowski 2012). 
 
1.5 Leucyl-tRNA Synthetase or Folliculin; Which One Acts as a GTPase 
Activating Protein for Rag C/D? 
 
 
Upon introduction of LeuRS as a sensor for Leu availability in the cytoplasm, a 
further investigation was carried out to unveil the mechanism through which 
LeuRS relays the signal to mTORC1. Immunoprecipitation analyses between 
LeuRS and Rags along with in-vitro GTPase assays implicated LeuRS as a 
GTPase-activating protein (GAP) for Rag D (Han et al. 2012). Follow-up 
analyses, however, failed to confirm LeuRS as the active GAP of RagD but 
identified Folliculin (Flcn) to be the protein to carrying out these function. Being 
first identified as a tumor suppressor whose loss of function leads to Birt-Hogg-
Dube syndrome with characteristics including formation of benign tumors in hair 
follicles, lung and renal system (Nickerson et al. 2002), Flcn has been related to 
various pathways in the cell such as mTOR signaling, transforming growth factor 
β (TGF-β) signaling, AMP-activated protein kinase (AMPK) signaling, JAK-STAT 
signaling, cell adhesion, membrane traffic and cilia function (Petit, Roczniak-
Ferguson, and Ferguson 2013). Notably, Petit et al could shed light on a new 
function of Flcn in translocation of transcription factor EB (TFEB) between 
nucleus and cytoplasm; in that nuclear localization of TFEB was observed in Flcn 
knockdown cells. They also found Flcn function necessary for re-activation and 
lysosomal localization of mTORC1 after deprivation and replenishment of amino 
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acids consequently (Petit et al. 2013). In the search for implicating the 
significance of Rag C and D in amino acid signaling machinery, Tsun et al could 
substantiate GAP activity of Flcn towards Rag C and D (Tsun et al. 2013). Amino 
acid deprivation induces Flcn interaction with the lysosomal membrane, 
specifically to Rag C/D which is diminished by replenishment of amino acids. 
Accordingly, Flcn needs to detach from the lysosomal membrane to be replaced 
by mTORC1 in presence of amino acids (Tsun et al. 2013). Similar to Flcn, 
Folliculin interacting protein (FNIP) indirectly regulates mTORC1 activity and 
TFEB localization as suppression of FNIP induces nuclear localization of TFEB 
(Petit et al. 2013). Taking into account that FNIP is necessary for interaction of 
Flcn and Rags and Flcn is also necessary for FNIP-Rags interaction, Flcn and 
FNIP are considered as components of a complex in which both proteins should 
be active in order for Flcn to show GAP activity towards Rag D (Petit, Roczniak-
Ferguson, and Ferguson 2013; Tsun et al. 2013); since neither Flcn nor FNIP 
shows the activity, separately (Tsun et al. 2013). 
The notion that suppressing both LeuRS and Flcn expression inhibits 
translocation of mTORC1 to the lysosomal membrane in response to amino acid 
availability (Han et al. 2012; Tsun et al. 2013), inspired us to assess the 






1.6 Homocysteine; a Non-Proteinogenic Amino Acid 
In addition to essential and non-essential amino acids that are used for protein 
synthesis, there are amino acid metabolites some of which are detrimental to the 
cells (Dasuri et al. 2011). These side products, the so-called non-proteinogenic 
amino acids, need to get removed from the protein translation pathway to inhibit 
error insertion in proteins and formation of misfolded proteins that ultimately lead 
to cell death (Lee et al. 2006). Homocysteine, a known sulfur-containing non-
proteinogenic amino acid results from demethylation of Met (Prudova et al. 2006) 
and has been identified as a risk factor for cardiovascular disease (Garcia and 
Zanibbi 2004; Zhuo, Wang, and Pratico 2011). When plasma Hcy concentration 
exceeds 14 μM, we encounter hyperhomocysteinemia (HHcy), a pathological 
state which is linked to cardiovascular disease, neuronal cell death along with the 
loss of short and long-term memory (Ataie, Sabetkasaei, and Haghparast 2010; 
Zhuo et al. 2011; Kamat et al. 2013). Hyperhomocysteinemia has also been 
associated with Alzheimer’s disease (AD), schizophrenia and depression 
(Folstein et al. 2007). 
In process of losing a methyl group, Met converts to S-adenosine 
methionine (SAM) and eventually Hcy. Homocysteine needs to get re-methylated 
in order to convert to Met. 5-methyltetrahydrofolate, known as folic acid and SAM 
are main methyl donors to Hcy. Notably, methylenetetrahydrofolate reductase 
(MTHFR) and methionine synthase (MS) are the enzymes driving the re-
methylation pathway, though are important in the elimination of Hcy from the 
body (Chiang et al. 1996). The alternative enzyme proposed to have a positive 
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effect on the removal of Hcy is cystathionine β- synthase (CBS); the enzyme 
which demands vitamin B6 as an efficient cofactor to function optimally. The 
product of CBS activity is cystathionine which will ultimately be converted to 
cysteine and α-keto butyrate through a second enzymatic step (Jakubowski 
2012).  
Given that Hcy is a modified form of Met, it is possible that Hcy can be 
sensed by mTORC1 through AARS. The impact this Hcy may have on mTORC1 
activity was evaluated in this dissertation. 
 
1.7 mTORC1 Negatively Regulates Autophagy 
The transcription factor EB is a member of the basic helix-loop-helix leucine 
zipper family of transcription factors and shown to be a substrate of mTORC1 
(Sardiello et al. 2009). Upon mTOR-mediated phosphorylation of TFEB at serine 
211, TFEB interacts with the 14-3-3 protein which blocks TFEB’s nuclear 
localization signal. This way, phosphorylated TFEB remains in the cytoplasm 
(Martina et al. 2012; Roczniak-ferguson et al. 2012). Unphosphorylated TFEB 
translocates into the nucleus where it binds to a 10-base pair DNA motif 
(GTCACGTGAC), the so-called Coordinated Lysosomal Expression and 
Regulation (CLEAR). The CLEAR element is part of the promoter of genes 
encoding lysosomal and autophagosomal proteins (Sardiello et al. 2009) (Figure 
1.2). Thereby, TFEB induces lysosomal biogenesis and autophagy, a cellular 
self-eating process for degradation of protein aggregates and old organelles in 
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the cytoplasm (Glick, Barth, and Macleod 2010). Two of the crucial autophagy-
related TFEB target genes are ubiquitin-binding protein P62, (an adaptor protein 
that detects ubiquitinated protein aggregates and recruits them to the 
degradation initiation site, autophagosomes) (Lamark et al. 2009), and 
microtubule-associated protein 1 Light Chain 3 (LC3), which is necessary to 
detect targets selected for macro-autophagy degradation. LC3 is a member of 
Atg proteins which is either cytosolic (LC3-I) or membrane-bound (LC3-II). The 
transition between the two forms of protein occurs by cleavage of LC3 on its C-
terminal domain through a cysteine protease (Atg4) that is believed to expose it 
to further post-translational modification known as covalently phosphatidyl 
ethanolamine conjugation (Marino et al. 2002). The later modification renders 
LC3-II capable of binding to inner and outer part of autophagosomal membranes. 
Since LC3 detects ubiquitinated proteins and sequesters them in 
autophagosomes through the help of adapter proteins, ubiquitination could be 
considered as a signal for both proteasomal degradation and selective 
autophagy. The distinguishing factor deciding whether proteins should undergo 
proteasomal degradation or selective autophagy is binding of proteins to UBD 
(ubiquitin-binding domain)-containing autophagy receptors (such as P62) that 
simultaneously bind to Atg8 (LC3) proteins (Slobodkin and Elazar 2013). 
However, P62 is not dependent on LC3 to be recruited to autophagosomes; the 
PB1 (Phox1 & Bem1p) domain of p62 has been shown to be sufficient for its 
recruitment to autophagosomes, and starvation indeed boosts this process 




Figure 1.2 TFEB translocation in and out of the nucleus. Phosphorylation of 
TFEB by mTORC1 determines its localization; as phosphorylated TFEB is kept in 
the cytoplasm while unphosphorylated form enters the nucleus to render its role 
on transcription of CLEAR-gene network.    
 
The alternative factor which is influenced by mTORC1 activity and 
consequently affects autophagy initiation is unc-51 like autophagy activating 
kinase-1 (ULK1) which contains several phosphorylation sites that regulate its 
activity. Having a dual function in autophagy regulation, ULK1 is phosphorylated 
on various sites which determine its role in autophagy. Phosphorylation of ULK1 
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on serine 317 and serine 777 by AMP-activated protein kinase (AMPK) are 
crucial for induction of autophagy, while mTORC1 kinase activity on serine 757 of 
ULK1 hampers AMPK interaction to ULK1 and inhibits autophagy pathway (Kim 
et al. 2011). 
 
1.8 Low Rates of Autophagy in Alzheimer’s Disease Patients’ Brains   
As a protective mechanism, autophagy is initiated in response to abnormal 
conditions in the cells such as hypoxia, low energy level due to lack of amino 
acids and growth factors, aggregation of proteins, DNA damage (Mathew, 
Karantza-wadsworth, and White 2007) and metabolic stress (Levine and 
Kroemer 2008). Observation of enlarged autophagic vacuoles in patient cells of 
AD (Nixon and Yang 2011), Parkinson’s and Huntington’s diseases raised the 
speculation as whether autophagy is the cause for initiation of these diseases or 
can be used as a strategy to ameliorate the pathology of these conditions 
(Rubinsztein et al. 2007; Williams et al. 2006; Martinez-vicente and Cuervo 2007; 
Levine and Kroemer 2008). As autophagy is shown to remove paired helical 
filaments of tau protein aggregates (Williams et al. 2006), it is more compelling 
that autophagy has a positive impact on hampering of neurodegeneration and 
clearance of abnormal protein accumulations. On the other hand, AD is 
discussed by some researchers as a Lysosomal Storage Disease (LSD) due to 
lysosomal enzymes malfunction in degradation of cargos transported there 
(Nixon, Yang, and Lee 2008). Since aggregated proteins are large and can be 
cleared only by specific pathways in the cytoplasm such as macroautophagy, it is 
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significant for the pathway to run efficiently (Martinez-vicente and Cuervo 2007). 
To date, there is no evidence why autophagy is impaired in AD neurons. Here we 
introduce Hcy as one of the risk factors of AD and a possible inhibitory agent of 
autophagy.  
 
1.9 Significance and Introduction to Dissertation Project 
Dysregulation of mTORC1 activity has been correlated with the pathology of 
several human diseases such as cancer (Bar-peled et al, 2014), metabolic 
diseases, neurodegeneration, and aging process (Laplante and Sabatini 2012). 
Especially in the case of neurodegeneration, since intact autophagy and 
proteasomal protein degradation are known to have an important impact on 
inhibition of the disease onset (Rubinsztein 2006), mTORC1 signaling as a 
regulator of autophagy pathway has received attention and been the center of 
study in the field. By assessing mTORC1 activity in postmortem brains of human 
AD patients, we found up-regulation of mTORC1 kinase activity in AD samples 
as compared to controls (Figure 3.1 A). In parallel, high plasma levels of Hcy has 
been recorded for those AD patients as a highly plausible risk factor (Zhuo, 
Wang, and Pratico 2011; Li, Chu, and Barrero 2014; Kamat et al. 2015). Studies 
on Cbs deficient mice mated with double transgenic APP/PS1 mouse model of 
amyloidosis show that Hcy changes the ratios of the produced βA42 and βA40 
peptides to drive the amyloidogenic pathway (Pacheco-quinto et al. 2006). 
Moreover, a group of B vitamins has implicated inhibitory effects on brain 
shrinkage and cerebral atrophy in patients with HHcy, diagnosed with AD 
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(Douaud et al. 2013). Additionally, substantiated data show that vitamin B12 
deficiencies lead to cognitive impairment by induction of HHcy which is also 
linked to methylation deficiencies of myelin basic protein leading to neuronal 
defects (Sponne et al. 2000).  
Taken together, all these data support the notion that Hcy might elicit AD 
phenotype through different pathways, from activation of NMDA transporters 
(Lipton et al. 1997), to increase in activity of β-secretase (BACE) (Fuso et al. 
2005) and γ-secretase (Li et al. 2014). Yet, there is no link provided between 
Hcy-mediated mTORC1 activity and generation of AD phenotype. Here, we 
assess whether and how Hcy can be sensed by mTORC1 and explore the 
correlation between high plasma Hcy levels, mTORC1 hyperactivity, and 
autophagy inhibition in human and mouse neurons.    
 
1.10 The Hypothesis of the Dissertation 
Given that Hcy and mTORC1 activity, both are elevated in AD patients, it is 
worthwhile to evaluate Hcy contributions to mTORC1 activity and consequently 
on autophagy. In this dissertation we examined this hypothesis: Leucyl-tRNA 
synthetase (LeuRS) (an enzyme is known to load tRNA with leucine) 
regulates the activity of Folliculin (Flcn) (an mTORC1 activator) in a 
homocysteine/leucine-dependent manner; mTORC1 hyperactivity inhibits 
autophagy by phosphorylation of TFEB (a transcription factor) or ULK-1 (an 
autophagy inducer) and leads to neurodegeneration. To test this hypothesis 
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we utilized mainly HEK293T cells and iPSC-derived human neurons for in-vitro 
studies, as well as Cbs knockout mice for in-vivo analyses, and accomplished the 
following: 
1. Elucidated Hcy effect on mTORC1 activity in cells treated with Hcy and 
Cbs knockout mouse brain samples. 
 
2. Elucidated how LeuRS and Flcn cooperatively sense levels of cellular 
amino acids and their metabolites to activate mTORC1 in the Cbs deficient brain 
and cultured cells. 
 
3. Determined rate of autophagy induction in HEK293T cells and human 
neurons treated with Hcy. 
 
4. Determined TFEB activity in Hcy-treated cells and Cbs knockout mice 
brain samples. 
 















MATERIAL AND METHODS 
 
2.1 Materials 
2.1.1 Cell Lines 
2.1.1.1 HEK293T Cells. HEK293T cells are human embryonic kidney cells 
cultured and maintained in Dulbecco’s modified Eagle’s medium (DMEM) with 
10% Fetal Bovine serum (FBS), L-glutamine (Glu) and penicillin/streptomycin 
(Pen/Strep).  
 
2.1.1.2 Human iPS Cells. Human neural stem cells (also called neuroprogenitor 
cells) were generated in our lab using previously established human iPSC lines 
and following dual-SMAD inhibition protocols using SB431542 (10µM, Stemgent) 
and LDN193189 (250nM, Stemgent) drugs for at least three weeks and until the 
formation of neural rosettes was obvious. Neural rosettes were micro-dissected 
under a microscope in sterile environment (cell culture hood), trypsinized to 
dissociate into single cells, and maintained in neuroprogenitor basal media 
(#05834 Stem Cell Technologies) including supplement A (#05836) and 
supplement B (#05837) and differentiated to human forebrain neurons in 
neurobasal media supplemented with B27 without vitamin A (#12587-010), 
Glutamax and Pen/Strep, for at least three weeks. Successful differentiation has 
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been confirmed in immunofluorescence analyses showing loss of progenitor 
marker expression (Nestin) and gain of neuronal marker expression (Tuj1, 
MAP2, Synapsin1).   
 
2.1.1.3 CAD cells. CatecholAminergic Differentiated (CAD) cells are mouse 
neuroblastoma cells. CAD cells stably expressing TFEB under a doxycycline 
(DOX) sensitive promoter were established in our lab and cultured in normal 
DMEM 10% FBS similar to HEK293T cells. 
 
2.1.1.4 MEF cells. Mouse Embryonic Fibroblasts (MEFs) were cultured and 
maintained in DMEM supplemented with 10% FBS. 
 
2.1.2 Animals 
Transgenic Tg-I278T 𝐶𝑏𝑠−/− mice on C57BL/6J genetic background and their 
𝐶𝑏𝑠+/− littermates were bred and housed at the New Jersey Medical School 
Animal Facility. In these animals, the human CBS-I278T variant is under control 
of the zinc-inducible metallothionein promoter, which allows rescue of the 
neonatal lethality phenotype of 𝐶𝑏𝑠−/− by supplementing the drinking water of 
pregnant dams with 25 mM zinc chloride. Zinc water is replaced by plain water 
after weaning. The mice were fed a normal rodent chow (LabDiet5010, Purina 
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Mills International, St. Louis, MO). 12-month-old animals were used for 
immunohistochemistry studies.  
 
2.1.3 DNA constructs 
Plasmids were kindly provided by following laboratories: pRK5-HA GST RagC 
plasmids (Addgene #19304, 19305, 19306, Cambridge, MA, USA) and Flag-
Leucyl tRNA synthetase pRK5 (Addgene #46341) were gifts from Dr. David 
Sabatini (Whitehead Institute, Massachusetts Institute of Technology, 
Cambridge, MA, USA), ptfLC3 (Addgene #21074) was a gift from Dr. Tamotsu 
Yoshimori (Osaka University, Osaka, Japan), and ptdTomato-N1-FLCN 
(Addgene #49174) was a gift from Dr. Shawn Ferguson (Yale School of 
Medicine, NewHaven, CT, USA). The CLEAR-Luciferase construct was a 
generous gift from Dr. Andrea Ballabio (Telethon Institute of Genetics and 
Medicine (TIGEM), Pozzuoli, Italy). 
 
2.1.4 Antibodies 
The following were used as primary antibodies for immunostaining and 
immunoblotting: AKT (#4691P, Cell Signaling), Amyloid (#D54D2, Cell 
Signaling), β-Actin (#JLA20, DSHB), Flag (#F3165, Sigma), Flcn (#D14G9, Cell 
Signaling), HA (#024M4773, Sigma), mouse LAMP2 (#ABL-93, DSHB), human 
LAMP2 (#H4B4), LC3 a/b (#4108, Cell Signaling), LeuRS (#sc-130801, Santa 
Cruz), MAP2 (#ab5392, Abcam), mTOR (#7C10, Cell Signaling), P-4E-BP1 
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(#236B4, Cell Signaling), p62/SQSTM1 (GP62-C, Progen), P-Akt (Ser473, 
#4060P, Thr308, #2965P, Cell Signaling), P-p70S6K (Thr389, #9205, Cell 
Signaling), P70S6K (#2708, Cell Signaling), PHF pTau (#MN1020, 
ThermoFisher), PULK1 (Ser 757 #D706U, Cell Signaling), RagC (Rag antibody 
sampler kit, #9778, Cell Signaling), Rheb (#E1G1R, Cell Signaling), Sestrin2 
(#10795-1-AP, ProteinTech), TFEB (#MBS120432, Abcam for immunostaining; 
#ab2636, Abcam, for immunoblotting, and #A303-673A, Bethyl Biosci. for 
immunohistochemistry), Tuberin/TSC2 (#D93F12, Cell Signaling), Tubulin 
(#CP06, Calbiochem). Secondary antibodies were coupled to Infrared Dyes 
(LICOR, IRDye 680 and IRDye 800) or to HRP (Jackson IR) for immunoblotting, 
or to fluorochromes (Jackson IR) for immunostaining.  
 
2.1.5 Chemicals 
RPMI media without leucine/glutamine was supplied by US Biological. Amino 
acid starvation experiments were performed in the same media supplemented 
with L-glutamine (#R899912) and 10% dialyzed FBS (Reddy et al. 2016). RPMI 
complete media was prepared by addition of L-leucine (#L800) to the starvation 
media. DMEM provided by Sigma were supplied with glutamine, Fetal Bovine 
Serum (gibco), penicillin and streptomycin (gibco). Rapamycin was provided by 
Sigma (#R0395), and TAT-Beclin1 by EMD Millipore/Sigma (#5060480001). 
Amino acids (Sigma-Aldrich) were reconstituted in water. L-Hcy (#69453) and L-




Spinning disc confocal microscope (Zeiss, Oberkochen, Germany) with lasers 
emitting 488, 536/561, 639 and 405 nm laser lines and 63X oil immersion 




Cells were plated on coverslips coated with fibronectin, for one hour and fixed 
with 4% paraformaldehyde (PFA) for 15 minutes at room temperature. Cells were 
incubated with primary and fluorophore-tagged secondary antibodies and 
subjected to imaging in confocal microscopy.  
 
2.2.2 Immunohistochemistry 
Mice were perfused transcardially under deep pentobarbital anesthesia. Brains 
were collected, post-fixed in 4% PFA, and cryoprotected in 30% sucrose in PBS 
solution prior to sectioning. Thirty µm thick hippocampal brain sections from PFA 
perfused mice were rehydrated with PBS and permeabilized with 1% Triton X-
100 in PBS for 30 mins. The sections were washed 3 times for 10 minutes with 
PBS-Triton buffer (0.05% Triton X-100 in PBS), incubated in blocking buffer (50% 
NGS, 50% PBS-Triton buffer) for 2 hours, and in indicated primary antibody 
solution (50% blocking buffer, 50% PBS-Triton X-100) overnight at 4°C in 
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humidity chambers. The sections were washed with PBS-Triton buffer and 
incubated with fluorescently-labeled secondary antibodies for 2 h at room 
temperature and mounted. Sections were imaged with a Zeiss spinning disc 
confocal microscope, taking a Z-stack of 29 sections with an interval of 0.48μm 
and range of 13.45μm.  
 
2.2.3 SDS-PAGE and Immunoblot 
Cells were resuspended in lysis buffer (10% glycerol, 1% NP40, 20mM Tris 
(pH7.4), 2.5mM EDTA (pH8), 2.5mM EGTA (pH8) containing Roche Protease 
inhibitor cocktail (#04693116001) diluted according to manufacturer’s 
instructions) and cell lysates were centrifuged at 14000 rpm for 15 minutes at 
4°C. The cleared supernatants were collected and prepared for SDS-PAGE on 
10 or 12% mini gels; protein concentrations were determined using BCA reagent. 
Resolved proteins were transferred onto PVDF (Immobilon) membranes followed 
by a 45-minute room temperature incubation in western blocking solution (5% 
milk, 0.1% Triton X-100 in TBS). The membrane was incubated with primary 
antibodies overnight and with secondary antibodies for 45 minutes.  After washes 
in TBS-T, the membranes were analyzed using either an LI-COR Odyssey 







HEK293T cells were transfected with HA-RagC (wild type, constitutively active 
and dominant negative), LeuRS-Flag and Flcn-dTomato plasmids, separately 
followed by overnight culturing to reach appropriate confluency. IP-buffer (50mM 
Tris, 150 mM NaCl, 10mM EDTA, 1% NaF, 1% Na3VO4, 1% NP40, 0.5 mM 
DTT, 1x Complete Protease Inhibitor Cocktail (Roche)) was used for lysing the 
cells. Lysates were cleared by centrifugation and incubated overnight with anti-
HA/Flag antibodies at 4°C followed by overnight incubation with MagnaBind goat 
anti-rabbit/mouse beads (ThermoScientific) on a rotating mixer. After incubation, 
the beads were washed 3X with IP-buffer and then resuspended in Laemmli 
buffer and boiled for 10 mins. The IP protein samples and protein input were 
analyzed by SDS-PAGE and immunoblotting to examine endogenous LeuRS, 
Flcn, and RagC in all cell lines under different feeding conditions. 
 
2.2.5 EGFP-mRFP-LC3 Assays 
To assess the maturation and amount of active autophagosomes, ptfLC3 
constructs were transiently transfected into iPSC-derived human forebrain 
neurons. After 48 hours, some cultured cells were incubated with 100 uM 
Chloroquine for up to 1 hour to inhibit autophagy flux. Cells were fixed with 4% 
PFA, mounted and imaged. Images from approximately 100 cells per treatment 
were collected and quantified for the number of red puncta (mRFPLC3 signal) 
per cell; the GFP signal was recorded blindly, using same exposure times and 
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laser strength settings as for the RFP channel. A yellow signal indicates not 
acidified, immature autophagosomes. 
 
2.2.6 Luciferase assays 
4xCLEAR Luciferase construct containing four times repeated CLEAR element 
upstream of Firefly-luciferase gene has been used to assess the activity of TFEB 
and CLEAR gene network. In this assay, TFEB binding to CLEAR promoter 
drives the transcription of TFEB-regulated genes and luciferase. Luciferase 
transcription is assessed in Dual-luciferase Reporter assays (Promega) for which 
cells were seeded in a 24 well plate and co-transfected with 4xCLEAR Luciferase 
and SV40 Renilla luciferase plasmids. SV40 Renilla luciferase was used as a 
transfection control. Twenty-four hours after transfection, cells were harvested in 
passive lysis buffer (Promega) and, after short centrifugation separating cellular 
membranes and DNA, 10 µl of pre-cleared lysate were used to assay luciferase 
activity using the Promega Dual-Luciferase Reporter kit and GloMax Multi+ plate 
reader. 
 
2.2.7 Aβ Assays 
Fully differentiated human forebrain neurons or mouse brain tissues were 
resuspended in the standard diluent buffer supplied by the manufacturer (Wako). 
To quantify Aβ levels human/mouse Aβ 1-40 and 1-42 ELISA kits (Wako) were 
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used according to the manufacturer’s instructions. All assays were repeated 3 
times and averaged for each triplicate. 
 
2.2.8 Quantification and Statistics 
All immunoblot signals were quantified using ImageJ software. To assess the 
number or co-localization of autophagosomes, lysosomes, and protein 
aggregates their specific, punctuate staining was quantified using ImageJ 
software and plugins for measuring intensity maxima from images based on 
individual parameters, or individually counted. Statistical evaluation of the 
collected data was performed using the student t-test and analysis of variance 
(ANOVA) as appropriate. Significant differences of means are indicated as *p < 












HOMOCYSTEINE ACTIVATES mTORC1 SIGNALING THROUGH 
INTERACTION WITH LeuRS-Flcn COMPLEX 
 
Amino acid sensitivity of mTORC1 is very well accepted in the field in that 
availability of amino acids activates mTORC1, provides its localization on the 
lysosomal membrane, and further increases protein synthesis (Hara et al. 1998); 
although how amino acid metabolite as modified forms of amino acids affect 
mTORC1 activity is yet to be assessed. Homocysteine (de-methylated form of 
methionine) is known as a risk factor for AD (Zhuo et al. 2011; Kamat et al. 
2015). Mutations in MTHFR, methionine synthase (MS) and CBS are known 
factors for AD pathogenesis (Garcia and Zanibbi 2004; Beyer et al. 2003; Zhuo et 
al. 2011). All three enzymes mentioned above are functional to remove excess 
Hcy from the body; MTHFR provides carbon group to folate which later donates it 
to Hcy and facilitates remethylation of Hcy to Met. MS is the main enzyme acting 
on Hcy methylation and Met production; whereas CBS is the enzyme that 
converts Hcy to cysteine in a two-step transsulfuration pathway. While MS needs 
vitamins B12 and B9, CBS needs vitamin B6 to function properly (Jakubowski 
2012). Here we elucidate the impact Hcy might have on mTORC1 activity by 
assessing the phosphorylation level of mTORC1 substrates and localization of 
mTORC1 in the cell. 
The amino acid sensitivity of mTORC1 is known to be fulfilled by multiple 
amino acid sensors in the cell. While v-ATPase detects the luminal content of 
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lysosomal amino acids (Zoncu et al. 2011), LeuRs (Han et al. 2012) and Sestrin2 
(Wolfson et al. 2016) are potent Leu sensors in the cytoplasm. In this chapter, we 
show a new mechanism for Hcy to be sensed and further regulate mTORC1 
activity. We show that Flcn which is known as a GAP for RagC/D (Tsun et al. 
2013), interacts with LeuRS and its activity is dependent on amino acid (including 
Hcy) availability.   
 
3.1 Results 
3.1.1 Homocysteine Treatment Increases Phosphorylation Level of 
mTORC1 Substrates 
 
It is well known that Leu is a strong mTORC1 activator which translocates 
mTORC1 on the lysosomal membrane where it is in close proximity to Rheb, its 
activator (Bar-Peled and Sabatini 2014). Given that mTOR is a kinase, its 
activation corresponds to increase in phosphorylation levels of its related 
substrates. Thus, to assess mTORC1 activity, the phosphorylation level of 
P70/S6K, 4EBP-1, and TFEB were analyzed in western blot analyses of cells 
treated with Hcy for three hours. HEK293T cells and iPSC-derived human 
neurons were main cell lines utilized for completion of this research project. Cells 
were cultured in RPMI media supplemented with Leu, Glu and 10% dialyzed FBS 
in which mTORC1 is fully active. Leucine withdrawal from the above media 
renders mTORC1 inactive and diffused in the cytoplasm; thus, we used it as 
starvation media for our experiments. In Hcy-treated conditions, Leu was 
substituted by Hcy; in this manner, we were able to evaluate and compare 
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mTORC1 activity in presence of Leu or Hcy. Homocysteine-treated cells showed 
increased mTORC1 activity compared to starved cells as was detectable by 
measuring the phosphorylation levels of P70/S6K, 4EBP-1, and TFEB (Figure 
3.2 A, B, and C). The activity of mTORC1 was up-regulated in presence of Leu 
and Hcy as compared to Leu alone (Figure 3.3 A, B, and C). These data showed 
Hcy ability to activate mTORC1 in absence or presence of Leu. Of note, 
immunoblot analyses of P70/S6K in human brain lysates of AD versus control 
patients showed increase of mTORC1 activity in AD patients (Figure 3.1 A), 
which were diagnosed with a high level of plasma Hcy (Zhuo et al. 2011; Li, Chu, 
and Barrero 2014; Kamat et al. 2015). However, levels of other mTORC1-related 
factors such as TSC2 and Rheb which inhibit and activate mTORC1 respectively 
did not show a significant difference between control and AD samples (Figure 3.1 
B and C). 
To elucidate the pathway through which Hcy leads to mTOR activation, 
and to rule out the possibility of Akt signaling activation by Hcy, Akt (T308) 
phosphorylation level was measured in immunoblot analyses of cells treated with 
ascending concentrations of Hcy. Although phospho-p70/S6K levels increased 
proportionally to increased concentrations of Hcy, phospho-Akt (T308) did not 
change significantly (Figure 3.4). Similarly, phospho-Akt (T308) and (S473) were 
probed in Cbs deficient and wild-type mice brain lysates; neither phospho-Akt 
(T308) (as a marker for growth factor signaling) nor phospho-Akt (S473) (as a 
readout for mTORC2 signaling) changed significantly between mutant and 
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normal mice (Figure 3.5 A and B). Interestingly, we did not observe significant 












Figure 3.1 mTORC1 is activated in postmortem brain samples of Alzheimer’s 
disease patients. A) The phosphorylation level of P70S6Kinase increased 
significantly compared to control patient samples. B and C) TSC2 (mTOR 
inhibitor) and Rheb (mTORC1 activator) protein levels did not change 
significantly between control and AD patients. Bar graphs represent a 
quantitative analysis of protein levels assessed by immunoblot analyses. Data 
































Figure 3.2- A, B, C Homocysteine up-regulates mTORC1 activity in absence of 
leucine. HEK293T cells were treated with RPMI media supplemented with Glu, 
dialyzed FBS and Hcy in absence of Leu (RPMI starvation media). A) 
Phosphorylation level of P70/S6kinase increased in Hcy-treated HEK293T cells 
which was indicative of mTORC1 hyperactivation (Leu: 3.1 +/- 0.4 -fold; Hcy: 2.7 
+/- 0.3-fold; P = 0.004). B) Phospho-4EBP-1 was measured in western blot 
analyses as an indicator of mTORC1 activity. Hcy increased P-4EBP-1 level in 
HEK293T cells (Leu: 2.4 +/- 0.3-fold; Hcy: 3 +/- 0.4-fold; P < 0.01). C) TFEB 
phosphorylation level was assessed to determine mTORC1 activity. Phospho-
TFEB appeared upon Hcy treatment while it was not present in starvation media 
without Hcy (Leu: 2.1 +/- 0.3-fold; Hcy: 3.2 +/- 0.4-fold; P = 0.014). Bar graphs 
represent a quantitative analysis of protein levels assessed by immunoblot 
analyses. Data are means +/- SEM (n = 6 independent experiments). *P ≤ 0.05, 




























Figure 3.3- A, B and C Homocysteine and leucine collaboratively activate 
mTORC1. HEK293T cells were treated with RPMI media supplemented with Leu, 
Glu, dialyzed FBS (RPMI complete media) and Hcy. A) Phospho-P70/S6K 
increased in media contained both Hcy and Leu. B) Phospho-4EBP1 increased 
in presence of Hcy and Leu in the media. C) Homocysteine and Leu together 
gave rise to the formation of a more phosphorylated form of TFEB. Bar graphs 
represent a quantitative analysis of protein levels assessed by immunoblot 
























Figure 3.4 Homocysteine regulates mTORC1 activity without changing the 
phospho-Akt pathway. HEK293T cells were treated with increasing 
concentrations of Hcy added to RPMI starvation media. Cell lysates were 
subjected to western blot analyses followed by probing with P-AKT (pT308) 
antibody. Homocysteine did not change phosphorylation levels of AKT(T308) 
while it did change phospho-P70/S6kinase levels, significantly (0.34 mM: 1.5 +/- 
0.2-fold; 4.25 mM: 3.5 +/- 0.4-fold). Bar graphs represent a quantitative analysis 
of protein levels assessed by immunoblot analyses. Data are means +/- SEM (n 









Figure 3.5- A and B Homocysteine does not impact phospho-AKT pathway in 
𝐶𝑏𝑠−/−  mice. A) Relative phospho-Akt protein levels associated with mTORC2 
signaling (phospho-Serine 473), as well as B) phospho-Akt indicative of growth 
factor receptor signaling (phospho-Threonine 308) did not significantly change in 
𝐶𝑏𝑠−/−  mouse brains compared to control littermates. Immunoblots represent 
separate runs of protein samples from five control and five knockout brains. Bar 
graphs represent quantitative analysis of protein levels assessed by immunoblot 




















Figure 3.6 Phosphorylated levels of AKT473 do not change in Alzheimer’s 
disease patients. Human brain lysates of Alzheimer’s and control patients were 
assessed in western blot analyses for determination of P-AKT473 levels. No 
significant changes were detected between our experimental groups. Bar graphs 
represent a quantitative analysis of protein levels assessed by immunoblot 
analyses. Data are means +/- SEM (n = 3 independent experiments). 
 
3.1.2 Mechanistic Target of Rapamycin is not Activated by Homocysteine-
Thiolactone 
 
Hcy-thiolactone, a reactive Hcy metabolite, has been detected in patients with 
high serum Hcy (HHcy). The reason for Hcy conversion to Hcy-thiolactone arises 
from Hcy editing process which happens by AARS through which Hcy takes a 
cyclized conformation. Homocysteine-thiolactone (a cyclic thioester) is known as 













(Jakubowski 2015). The hyperactivity of Hcy-thiolactone leads to protein damage 
and precipitation, hence is proposed to have pathological effects (Jakubowski 
1999; Akchiche et al. 2012); however, in our study, we showed that Hcy-
thiolactone did not regulate mTORC1 activity. HEK293T cells were treated with 
same concentrations of Hcy-thiolactone as Hcy in media with or without Leu. The 
activity of mTORC1 did not change in presence and absence of Hcy-thiolactone 
which was assessed by measuring the phosphorylation level of p70/S6K (Figure 














Figure 3.7 Homocysteine-thiolactone does not affect mTORC1 activity. 
HEK293T cells were cultured in RPMI complete and starvation media with or 
without Hcy-thiolactone. Phospho-P70/S6kinase was assessed by western blot 
analysis. No significant changes were observed in Hcy-thiolactone versus control 
treatments. Bar graphs represent a quantitative analysis of protein levels 





To confirm the data that identified Hcy-thiolactone as not incorporating into 
mTORC1 activation, Blmh/Pon1 deficient mice which lack both important 
enzymes to hydrolase Hcy-thiolactone were fed with Met, as a Hcy precursor, 
and brain lysates were applied to western blot analyses. It has been shown that 
these transgenic mice have a high concentration of Hcy-thiolactone in their 
plasma (Borowczyk et al. 2012). Normal mice fed with Met were used as a 
control that demonstrated higher mTORC1 activity compared to normal mice fed 
with water. However, Met-treated mice which were deficient in Blmh/Pon1 
enzymes did not show significant changes in mTORC1 activity compared to 












Figure 3.8 mTORC1 activity is not affected by homocysteine-thiolactone in-vivo. 
Brain lysates of normal mice fed with water or methionine and mice deficient in 
Bleomycin/Paraoxonase1 which was fed with methionine were subjected to 
western blot analyses. No significant changes in P-p70S6kinase activity were 
assessed between the normal and deficient mice fed with methionine. Bar graphs 
represent a quantitative analysis of protein levels assessed by immunoblot 
analyses. Data are means +/- SEM (n = 3 independent experiments). 
37 
 
Since Hcy is converted to the amino acid cysteine upon accumulation in 
the cells, the impact cysteine might have on mTORC1 activity was measured to 
specify the effect Hcy has on mTORC1, specifically. HEK293T cells were treated 
with RPMI complete and starvation media with or without cysteine. Cells were 
lysed further and subjected to western blot analysis. Phospho-p70S6kinase level 

















Figure 3.9 Cysteine does not affect mTORC1 activity. The effect of cysteine on 
mTORC1 activity was assessed in HEK293T cells by treating with cysteine in 
complete and starvation media and performing western blot analyses. No 
significant changes were observed in mTORC1 activity between our cysteine-
treated versus control cells. Bar graphs represent a quantitative analysis of 




3.1.3 Homocysteine Induces mTORC1 Localization on the Lysosomal 
Membrane in Absence of Leucine 
 
mTORC1 localization plays an important role in its activation in that the kinase 
needs to tether to lysosomal membranes to become activated (Sancak et al. 
2010), so localization of mTORC1 was monitored in immunostaining experiments 
by applying mTORC1 and lysosome-associated membrane glycoprotein 2 
(LAMP2) antibodies to cells treated with Hcy. In RPMI complete media virtually 
all of the mTORC1 co-localized with LAMP2; whereas, in RPMI starvation media 
which is deprived of Leu, mTORC1 diffused in the cytoplasm. The addition of Hcy 
to RPMI starvation media re-tethered mTORC1 back to the lysosomal 
membranes; hence indicating that Hcy can be detected by the amino acid 
sensing machinery that binds mTORC1 to LAMP2-positive membranes. Data 
were representative of two different cell lines; HEK293T cells (Figure 3.10 A) and 
mouse embryonic fibroblast (MEFs) (Figure 3.10 B). 
To further investigate the role of Hcy in-vivo we performed 
immunohistochemistry on Cbs deficient and wild type hippocampal sections. Cbs 
deficient mice showed increased co-localization levels of mTORC1 and LAMP2. 
Interestingly, overall protein levels of mTORC1 increased in these mice, whereas 
the number of their lysosomes decreased significantly compared to control 














Figure 3.10-A Homocysteine drives mTORC1 localization on lysosomal 
membrane. HEK293T cells were treated with RPMI complete and starvation 
media with or without Hcy. mTORC1 and LAMP2 antibodies were used to probe 
mTORC1 and lysosomes, respectively. DAPI stained nucleus. While mTORC1 
was diffused in the absence of Leu in starvation media, it localized on the 
lysosomal membrane in media which contained Hcy as a substitution for Leu. 
The inset shows magnification of selected fields. Scale bars are 10 µm. A bar 
graph is representative of mTOR/LAMP2 co-localization divided by the number of 
LAMP2 positive puncta. Data are means +/- SEM (n = 6 independent 























Figure 3.10-B Homocysteine drives mTORC1 localization on lysosomal 
membrane. MEFs were treated with RPMI complete and starvation media with or 
without Hcy. mTORC1 and LAMP2 antibodies were used to probe mTORC1 and 
lysosomes, respectively. DAPI stained nucleus. While mTORC1 was diffused in 
the absence of Leu in starvation media, it localized on the lysosomal membrane 
in media which contained Hcy as a substitution for Leu. The inset shows 







Figure 3.11 mTORC1 localizes on lysosomal membrane in 𝐶𝑏𝑠−/− mouse 
brains. Control and 𝐶𝑏𝑠−/− mouse hippocampal dentate gyrus sections were 
stained with mTOR and LAMP2 antibodies as markers for mTOR and lysosomes, 
respectively. DAPI stained nucleus. 𝐶𝑏𝑠−/−  mice hippocampi showed higher 
mTORC1 and LAMP2 co-localization compared to their control littermates (3.7 +/- 
0.5-fold vs. controls; P = 0.045). The bar diagram is representative of the number 
of mTOR and LAMP2 in control and knockout mice. The representative plot 
profile shows co-localization of mTOR and LAMP2 in 𝐶𝑏𝑠−/−  and control 
hippocampi; trendline indicates the average co-localization in the given image. 





3.1.4 Leucyl-tRNA Synthetase and Folliculin Interact as a Permanent 
Complex 
 
Leucyl-tRNA synthetase is not only known as a facilitator of tRNA-amino acid 
binding but also is recognized as a Leu sensor in the cell (Han et al. 2012). The 
affinity of Hcy in binding to LeuRS during the editing process of Hcy by LeuRS 
(Jakubowski 2012) raised the possibility that Hcy relays the signal to mTORC1 
through LeuRS. Although GAP activity of LeuRS toward Rag C was also 
proposed by Han et al (Han et al. 2012), the results could not be reproduced by 
other research groups in the field. Shortly after, Tsun et al introduced Flcn as a 
potent GAP for Rag C and D (Tsun et al. 2013). During this dissertation we 
tested the hypothesis that LeuRS and Flcn might interact with each other in an 
amino acid-dependent manner. To check this hypothesis we performed co-
immunoprecipitation assays testing whether Flcn would bind to LeuRS under 
certain metabolic conditions. For this purpose, HEK293T cells were transfected 
with Flcn-dTomato construct and treated in RPMI complete and starvation media 
with or without Hcy. Following immunoprecipitation, immunoblot analyses were 
performed to detect endogenous levels of LeuRS. Notably, we found the 
constitutive interaction between LeuRS and Flcn but did not detect a change in 
such interaction upon different amino acid treatments or in the starvation media 
(Figure 3.12 A). 
To confirm our data, reciprocal immunoprecipitation was performed in 
which HEK293T cells were transfected with LeuRS-Flag and endogenous Flcn 
was probed on western blot analyses. The same constitutive interaction was 
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detected between LeuRS and Flcn in all treatments which indicated that Flcn and 





















Figure 3.12-A and B LeuRS interacts with Flcn to form a complex, permanently. 
A) HEK293T cells were transfected with LeuRS-Flag plasmid and treated with 
RPMI complete and starvation media with or without Hcy. Cell lysates were 
subjected to Immunoprecipitation analyses followed by probing with Flcn 
antibody in western blotting. B) Whereas, reverse immunoprecipitation were 
applied by over-expression of Flcn-dTomato followed by LeuRS antibody staining 
in western blot analyses. Data is indicative of LeuRS and Flcn interaction in 
presence and absence of Leu or Hcy, constitutively. IgG pull-down was done as 





3.1.5 Leucyl-tRNA Synthetase-Folliculin Complex Interacts with Rag C 
Conditionally 
 
Folliculin, a tumor suppressor has been implied to have GAP activity toward Rag 
C/D; in that Flcn switches GTP-bound form of Rags for GDP and detaches from 
the lysosomal membrane as amino acids are replenished in the cytoplasm (Tsun 
et al. 2013). Here we provided evidence that Flcn localization is dependent on 
Hcy or Leu availability in the cell through two different experimental approaches. 
First, we examined the possibility of LeuRS-Flcn complex conditional interaction 
with Rag C. We performed immunoprecipitation analyses by transfecting 
HEK293T cells with RagC-HA construct and probing western blots with Flcn and 
LeuRS antibodies. The potent interaction between the complex and Rag C was 
observed only in absence of Leu or Hcy (Figure 3.13 A). Rag C constitutively 
active and dominant negative mutants were used as controls for the experiment. 
Reciprocal immunoprecipitation assays were conducted by transfecting the cells 
with LeuRS-Flag following by evaluation of endogenous Rag C levels in 
immunoblot analyses. Intense interaction between LeuRS-Flag and Rag C was 
detected in cells treated with starvation media. Whereas, LeuRS-Flag and Rag C 
interaction was virtually lost in presence of Leu, Hcy or both (Figure 3.13 B). 
In an alternative approach, localization of Flcn was assessed in confocal 
immunofluorescence analyses. We used Flcn antibody to check endogenous 
levels of Flcn (Figure 3.14 A) or transfected HEK293T cells with Flcn-dTomato 
construct to investigate the localization of exogenous overexpressed Flcn (Figure 
3.14 B). Cells were treated with RPMI complete and starvation media with or 
without Hcy. Folliculin and LAMP2 antibodies were applied to monitor Flcn and 
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lysosomes, respectively (Figure 3.14 A). In order to inhibit LeuRS-driven 
mTORC1 activity, leucinol, a Leu derivative, was applied which competes with 
Leu in binding to LeuRS (Han et al. 2012). Data depicted increased co-
localization of Flcn and lysosomes in starvation media and in leucinol treated 
cells even in presence of Hcy; while Flcn was diffused in the cytoplasm of cells 
treated with Leu or Hcy (Figure 3.14 A). We observed the same pattern of 
overexpressed Flcn localization in the cells according to amino acid and Hcy 
availability (Figure 3.14 B). 
 
Figure 3.13-A and B LeuRS-Flcn complex binds to RagC conditionally. A) 
HEK293T cells were transfected with RagC-HA plasmid and treated with RPMI 
complete and starvation media with or without Hcy. Co-IP samples were probed 
for endogenous LeuRS and Flcn in immunoblot analyses. Data indicates that 
LeuRS and Flcn interact with RagC in absence of Leu or Hcy (starvation media). 
Cells were also transfected with RagC-GTP-bound (dominant negative) and 
RagC-GDP-bound (constitutively active) as negative and positive controls, 
respectively. IgG pull-down was done as a control for immunoprecipitation. (n = 3 
independent experiments). B) HEK293T cells were transfected with LeuRS-Flag 
in complete and starvation media with or without Hcy. Further, immunoblots were 
probed for endogenous RagC. RagC showed the highest interaction with LeuRS 





















































Figure 3.14-A Folliculin diffuses in the cytoplasm in presence of homocysteine. 
HEK293T cells were examined for endogenous Flcn. Cells were cultured in RPMI 
complete and starvation media with or without Hcy. Leucinol was used as an 
mTORC1 inhibitor in presence of Hcy. Flcn and LAMP2 (as a lysosomal marker) 
antibodies were used in immunostaining experiments. DAPI stained nucleus. 
Flcn (white arrowheads) resided on lysosomal membrane in absence of Leu or 
Hcy, but diffused in the cytoplasm in presence of either of them. Magnifications of 





Endogenous Flcn staining 
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Figure 3.14-B Folliculin diffuses in the cytoplasm in presence of homocysteine. 
HEK293T cells were transfected with Flcn-dTomato. Cells were cultured in RPMI 
complete and starvation media with or without Hcy. Leucinol was used as an 
mTORC1 inhibitor in presence of Hcy. LAMP2 (as a lysosomal marker) 
antibodies were used in immunostaining experiments. DAPI stained nucleus. 
Flcn resided on lysosomal membrane in absence of Leu or Hcy, but diffused in 
the cytoplasm in presence of either of them (Hcy starvation conditions: 0.7 +/- 0.1 
vs. Leu: 0.1 +/- 0.002 and Hcy: 0.2 +/- 0.04; P = 0.01). Bar diagram is 
quantitative analyses of Flcn-LAMP2 co-localization divided by the number of 
LAMP2-positive puncta. Data are means +/- SEM (n = 6 independent 
experiments). Scale bars are 10 µm. **P ≤ 0.01. 
 
3.1.6 Sestrin2 Protein Levels are not Affected by Homocysteine 
Sestrin2 has been implicated as a Leu sensor which is capable of binding to Leu 
and activating mTORC1 (Wolfson et al. 2016). In general, Sestrin2 is an 
interacting partner for GATOR2 (an mTOR activator) and prevents mTORC1 
activity by disrupting GATOR2 function (Chantranupong et al. 2014). In presence 
of Leu, Sestrin2 loses interaction with GATOR2, renders induction of GATOR2-
GATOR1 interaction and attenuation of GATOR1-inhibitory effects on mTORC1 
which leads to increase in mTORC1 activity; thus the binding ability of Sestrin2 to 
Leu is necessary for it to activate mTORC1 (Chantranupong et al. 2014; Wolfson 
et al. 2016). 
In order to evaluate if the Hcy regulates Sestrin2 expression level in the 
cell, the protein levels of Sestrin2 were assessed in HEK293T cells upon 
treatment with Hcy. Data showed no significant change in Sestrin2 protein levels 
when cells were exposed to Hcy (Figure 3.15 A). Similarly, brain lysates of Cbs 
deficient mice did not show alterations in Sestrin2 levels compared to wild-type 





















Figure 3.15-A Homocysteine does not influence Sestrin2 protein expression 
levels. HEK293T cells were treated with different concentrations of Hcy. Sestrin2 
protein levels did not change with Hcy treatments. Bar graphs represent a 
quantitative analysis of protein levels assessed by immunoblot analyses. Data 























Figure 3.15-B Homocysteine does not influence Sestrin2 protein expression 
levels. Cbs knockout brain lysates were assessed for the levels of Sestrin2 
protein. Sestrin2 protein levels did not change in hyperhomocysteinemic mice 
brain samples. Bar graphs represent a quantitative analysis of protein levels 
assessed by immunoblot analyses. Data are means +/- SEM.  
 
3.2 Conclusion 
mTORC1 is capable of detecting the availability of amino acids in the cytoplasm 
through the complex machinery residing on the lysosomal membrane (Settembre 
et al. 2013). In this chapter, it was shown that mTORC1 is capable of sensing 
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cellular Hcy. Additionally, we proposed the interaction between LeuRS and Flcn 
in a constitutive complex to which Hcy bound and induced cellular translocation 
of the complex; LeuRS and Flcn lost binding to RagC when Hcy was present. 
This notion lent support to the hypothesis that LeuRS-Flcn complex acts as an 
alternative machinery which substitutes mTORC1 on the lysosomal membrane in 
starvation conditions. Further, we showed that Hcy-mediated mTORC1 activity 
was only specific to Hcy and not to Hcy metabolites in the cell such as Hcy-
thiolactone and cysteine. Finally, the protein levels of Sestrin2, a Leu sensor in 
the cytoplasm did not significantly change in response to Hcy. Overall, in this 
chapter, we showed that the amino acid metabolite Hcy is a potent inducer of 














ACUTE AND CHRONIC HOMOCYSTEINE TREATMENTS INHIBIT 
AUTOPHAGY INDUCTION THROUGH INACTIVATION OF ULK1 AND TFEB 
 
Autophagy is a cellular "self-eating" process that clears cytosolic protein 
aggregates and defective organelles and begins by the formation of a double 
membranous phagophore. In this process, proteins such as LC3 and P62 play 
role in phagophore maturation and autophagosome formation. Further, 
autophagosomes fuse with lysosomes to lyse their contents and provide amino 
acids and energy available to the cells (Glick, Barth, and Macleod 2010). 
Mechanistic target of rapamycin as a master regulator of nutrient signaling 
controls autophagy through phosphorylation of TFEB (Settembre et al. 2012; 
Martina et al. 2012) and ULK1 (Kim et al. 2011). During starvation conditions, 
mTORC1 is inactive and TFEB is no further phosphorylated; during these 
conditions, phospho-TFEB moiety is dephosphorylated by calcineurin, a required 
step for TFEB translocation into the nucleus. Consequently, active TFEB enters 
the nucleus and transcribes genes encoding autophagosome and lysosomal 
biogenesis. On the other hand, ULK1 interaction with AMPK is necessary for 
autophagy initiation which is impinged by mTORC1-mediated phosphorylation of 
ULK1 at Ser 757 (Kim et al. 2011). Since we showed that Hcy regulates 
mTORC1 activity, we investigate the consequences of Hcy-mediated mTORC1 
activation on the autophagy pathway in acute Hcy-treated or chronic 




4.1.1 Acute Homocysteine Treatments Impinge Autophagy Induction 
Unc-51 like autophagy activating kinase-1 (ULK1) and TFEB are two known 
autophagy regulators and mTORC1 substrates (Kim et al. 2011; Settembre et al. 
2012). We assessed the rate of autophagy induction in short term Hcy-treated 
cells. Cells co-transfected with LC3-RFP and LAMP1-GFP constructs were 
treated with Hcy for three hours and imaged searching for LC3-positive 
organelles. Homocysteine-treated cells showed a reduced number of LC3 
punctal staining compared to cells treated with control complete media. Torin, a 
specific mTOR inhibitor, and potent autophagy inducer, was added to Hcy-
containing medium and could reverse the diffused LC3 by increasing the number 
of LC3-positive organelles which co-localized with LAMP1 (late endosome and 
lysosomal marker) (Figure 4.1). 
Since mTORC1 phosphorylates ULK1 relatively quickly, we analyzed 
levels of phospho-ULK1 along with a lipidated form of LC3 (LC3II) in western 
blots. To decide what time point is the best for short-term Hcy treatments, 
HEK293T cells were treated with the same concentration of Hcy over different 
periods of time (1h, 2h, 3h, 4h, and 5h). Evaluation of cell lysates on western blot 
identified three hours of treatment with Hcy as a time point showing a reliable 
increase of mTORC1 activity in-vitro, as was assessed by evaluation of P-
p70S6/kinase level relative to protein loading control (Figure 4.2). To assess the 
true amount of LC3II formation in the autophagosomes prior to its lysosomal 





Figure 4.1 Acute treatments of homocysteine impinges autophagy induction. 
HEK293T cells were co-transfected with LC3-RFP and LAMP1-GFP constructs 
and treated with RPMI complete media with or without Hcy. Torin was used as a 
specific mTOR inhibitor. Chloroquine was utilized as a positive control for 
malfunctioned lysosomes. DAPI stained nucleus. Homocysteine reduced 
formation of LC3-positive autophagosomes (white arrowheads), while Torin 
rescued this phenotype and increased the formation of LC3 puncta (Leu, control: 
5.2 +/- 0.6 and Leu+Hcy: 1.1 +/- 0.1; P = 0.05), and (Torin in Hcy-treated cells: 
14.5 +/- 1.6; P = 0.04). Bar diagram represents quantitative analyses of LC3-
positive organelles per cell (red) and LC3-LAMP1 co-localization divided by the 
number of LAMP1-positive puncta (yellow). Data are means +/- SEM (n = 3 

























Figure 4.2 Three hours of homocysteine treatment show the strongest impact on 
mTORC1 activity. Treatment of HEK293T cells with same concentrations of Hcy 
at different time points showed that 3 hours of Hcy-treatments had the highest 
impact on mTORC1 activity which was measured by evaluation of relative P-
p70S6kinase protein levels. Bar graphs represent a quantitative analysis of 
protein levels assessed by immunoblot analyses. 
 
lysosome inhibitor such as Chloroquine was combined with experimental 
treatments to let us compare the overall amount of LC3II generated by cells and 
becomes degraded in lysosomes (Mizushima, Yoshimori, and Levine 2010). 
Interestingly, cells exposed to Hcy for three hours showed considerably 
decreased levels of LC3II and relatively increased levels of phosphorylated ULK1 
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on Ser 757 (Figure 4.3). The connection between the two comes from the fact 
that phosphorylation of ULK1 on Ser 317 & Ser 777 by AMPK is necessary for 
induction of autophagy whereas ULK1 phosphorylation on Ser 757 inhibits 
















Figure 4.3 Acute homocysteine treatments inhibit autophagy induction by 
increasing the level of phospho-ULK1. Human neuroprogenitor cells were treated 
with Hcy, Leu (for 3 hours) and Chloroquine (for 1 hour). Homocysteine clearly 
reduced the formation of LC3II (0.4 +/- 0.03-fold; P = 0.04) which was in parallel 
with an increase in the formation of P-ULK1 (1.5 +/- 0.03-fold; P = 0.05) which 
was indicative of less autophagy induction in the cells. Chloroquine treated cells 
showed a thicker LC3II band in absence of Hcy compare to its presence. Bar 
graphs represent a quantitative analysis of protein levels assessed by 
immunoblot analyses. Data are means +/- SEM (n = 3 independent experiments). 
*P ≤ 0.05. 
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An alternative approach to validate the hypothesis of autophagy inhibition 
by Hcy was to employ ptf-LC3 constructs, a tandem-fluorescent LC3 sensor as 
established by Kimura et al (Kimura, Noda, and Yoshimori 2007). ptf-LC3 has 
been constructed as a fusion protein of LC3, mRFP, and GFP, as such both red 
and green fluorescents are monitored in neutral pH environment whereas GFP is 
quenched in acidic organelles and only red is visible. Thus, in this experiment red 
organelles in merge channel are representative of functional lysosomes. Human 
neuroprogenitor cells were transfected with the construct and treated with RPMI 
complete and starvation media with or without Hcy and Chloroquine. Media 
containing Hcy reduced number of both red and green LC3-positive organelles 
which were indicative of a decline in both LC3 lipidation and autophagosomal 
maturation. Chloroquine which interferes with lysosomal acidification was used 
as a control for this experiment (Figure 4.4).  
 
4.1.2 Chronic Homocysteine Treatments Interfere with Autophagy Induction 
through Modulation of TFEB-Regulated Gene Expression 
 
Autophagy is known to be regulated by mTORC1 also through translation 
modulation of the TFEB-regulated genes (Martina et al. 2012). We took different 
approaches to test if TFEB is affected by the Hcy-driven mTORC1 activity. We 
performed autophagy flux assays to monitor LC3I and II protein levels in 
prolonged treatments with Hcy (16-24 h). Both LC3I and II significantly 
decreased in Hcy-treated cells as compared to cells treated with control media. 
The combination of treatments with Chloroquine depicted the reduced formation 
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of LC3II compared to Chloroquine treatments alone which were indicative of a 
reduction in autophagy induction (Figure 4.5). To analyze further the impact of 
long-term Hcy treatment on cells, we tested the protein levels of TFEB-target 
genes in wild type and Cbs deficient mouse brain lysates. Analyses showed 
reduced protein levels of both LC3I and p62 in mutant versus normal mice 
(Figure 4.6). Both of these experiments delineated the Hcy possible impacts on 




















Figure 4.4 Homocysteine interferes with autophagy induction. Human 
neuroprogenitor cells were transfected with tandem-fluorescent mRFP-GFP-LC3 
constructs and treated with RPMI complete and starvation media with or without 
Hcy. DAPI stained nucleus. Red arrowheads showed acidified autophagosomes 
while yellow ones were indicative of immature autophagosomes; both red and 
yellow puncta were reduced in presence of Hcy in the media which was 
indicative of inhibition of autophagy induction and maturation of autophagosomes 
(Leu (red): 3.1 +/- 0.3, Leu (green): 1.1 +/- 0.1; Hcy (red): 1.4 +/- 0.1, Hcy 
(green): 1.3 6 0.1; P = 0.04). Bar diagram is quantitative analyses of LC3 red and 
green signals per cell. Data are means +/- SEM (n = 3 independent 














Figure 4.5 Autophagy is inhibited by homocysteine, chronically. Human 
neuroprogenitor cells were treated with Leu, low concentration of Hcy (overnight) 
and Chloroquine (for 1 hour). Homocysteine clearly reduced the formation of 
LC3I (Leu/Hcy/CQ: 0.46 +/- 0.01-fold vs. Leu/CQ: 1.7 +/- 0.2-fold; P = 0.03) and 
LC3II (Leu/Hcy/CQ: 0.9 +/- 0.1-fold vs. Leu/CQ: 2.2 +/- 0.2-fold; P = 0.04) which 
were indicative of inhibition in autophagy induction and flux over longer period of 
Hcy-treatments. Chloroquine treated cells showed accumulation of LC3II in 
absence of Hcy. Bar graphs represent a quantitative analysis of protein levels 
assessed by immunoblot analyses. Data are means +/- SEM (n = 3 independent 














Figure 4.6 TFEB-target gene protein levels decreased in 𝐶𝑏𝑠−/− mouse 
samples. Brain lysates of Cbs deficient and wild type mice were subjected to 
western blot analyses. TFEB target genes (P62 and LC3) decreased in 𝐶𝑏𝑠−/− 
mice samples compare to control ones (LC3, 0.5 +/- 0.06, P = 0.01; p62, 0.6 +/- 
0.07 vs. 1.0 +/- 0.01 in controls, P = 0.04). Bar graphs represent quantitative 
analysis of protein levels assessed by immunoblot analyses. Data are means +/- 
SEM (n = 4 independent experiments). *P ≤ 0.05 and **P ≤ 0.01. 
 
4.1.3 Transcription Factor EB Activity is Impaired in Homocysteine-Treated 
Cells 
 
As a transcription factor, TFEB functions in the nucleus; mTORC1 kinase activity 
inhibits TFEB activation by maintaining TFEB in the cytoplasm far from its target 
genes (Martina et al. 2012). To assess TFEB activity we used four times CLEAR 
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element upstream of the Firefly-luciferase gene to which promoter TFEB bound 
and drove transcription of the CLEAR gene network and luciferase, 
concomitantly. Human neuroprogenitor cells were transfected with the 4xCLEAR 
luciferase reporter construct and treated with ascending concentrations of Leu or 
Hcy overnight, followed by measurement of luciferase activity, representing 
CLEAR network activity. Data revealed a reduction in the network activity 
coordinated with increased concentrations of Leu and Hcy (Figure 4.7 A). 
Leucine showed stronger inhibitory effects on TFEB activity since the activity was 
attenuated more potently with Leu compared to same concentrations of Hcy 
(Figure 4.7 B). We also tried to remove Leu and Hcy after overnight treatments to 
see how fast TFEB activity was rescued. Our data showed that Leu removal 
retained TFEB activity faster compared to Hcy (Figure 4.7 C).  
 
4.1.4 Transcription Factor EB Localizes in the Cytoplasm of Cells Treated 
with Homocysteine 
 
Given that our data showed a reduction in TFEB activity of cells exposed to Hcy, 
we tested the localization of this transcription factor in Hcy-treated cells and 
hyperhomocysteinemic mice brains. Mouse neuroblastoma cells stably 
expressed TFEB-Flag were treated with Hcy and stained with Flag antibody. 
Transcription factor EB is known to shuttle back and forth from cytoplasm to the 
nucleus upon presence and absence of amino acids, respectively (Settembre et 
al. 2012); we observed a similar TFEB translocation in presence and absence of 
Leu. Interestingly, TFEB localized to the cytoplasm of cells starved for Leu but 
62 
 
treated with Hcy, while leucinol combination translocated TFEB back to the 

















Figure 4.7- A, B and C CLEAR network activity is attenuated in response to 
homocysteine treatments. A) TFEB-driven CLEAR network activity was 
measured following transfection of human progenitor neurons with CLEAR-
luciferase construct and treatment with Leu or Hcy overnight. Data revealed a 
reduction in the network activity coordinated with increased concentrations of Leu 
and Hcy. It also showed that Leu had a stronger effect on inhibition of CLEAR 
activity compared to Hcy. B) Equal concentrations of Leu and Hcy were used to 
measure their inhibitory effect on CLEAR network activity over time. Data 
showed that Leu inhibited the CLEAR network activity faster than Hcy. C) After 
feeding the cells with Leu or Hcy overnight, cells were washed off Leu and Hcy 
followed by CLEAR activity measurement. Data indicated that Hcy potently 
inhibited CLEAR network activity compared to Leu since Leu deprivation showed 
a faster increase in the activity of the CLEAR network. Data are means +/- SEM 











Figure 4.8 Homocysteine drives TFEB out of the nucleus in cultured cell. Mouse 
neuroblastoma (CAD) cells stably expressed TFEB were treated with RPMI 
complete and starvation media with or without Hcy. While in absence of Leu, 
TFEB enters the nucleus, Hcy was able to draw TFEB back to the cytoplasm. 
Leucinol treatments could rescue the phenotype and translocated TFEB to the 
nucleus since leucinol inhibited Hcy effect on mTORC1 activity. Bar diagram 
shows the statistical evaluation of nuclear versus cytoplasmic localization of 
TFEB in the cells. Scale bars are 20 µm. 
 
Hippocampal sections of 𝐶𝑏𝑠−/− mice (in particular, dentate gyrus regions) 
were stained with TFEB and LAMP2 antibodies and compared with wild type. 
Most of the TFEB was observed in the cytoplasm of 𝐶𝑏𝑠−/− mice which was 
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exposed to high Hcy levels in the body whereas in wild type mice TFEB localized 
largely in the nucleus (Figure 4.9). 
 
Figure 4.9 Homocysteine inhibits TFEB translocation to the nucleus. 𝐶𝑏𝑠−/− 
versus wild type mice hippocampal neurons were applied to immunofluorescent 
staining. TFEB and LAMP2 antibodies were used as TFEB and lysosomal 
markers, respectively. TFEB was mostly nuclear in control neurons (72.4 +/- 13 
vs. 33 +/- 6% in 𝐶𝑏𝑠−/−; P < 0.01), while was cytoplasmic in Cbs deficient ones 
(67 +/- 10 vs. 28 6 4% in controls; P < 0.01). Bar diagram shows statistical 
evaluation of nuclear versus cytosolic localization of TFEB in mouse 
hippocampal neurons. Scale bars are 20 µm. Data are means +/- SEM (n = 5 






4.1.5 Leucinol Inhibits Homocysteine-Mediated mTORC1 Activity, Driving 
Higher Rate of Autophagy Flux 
 
Leucinol is a modified form of Leu with high affinity to bind to LeuRS. It is able to 
inhibit Leu binding to LeuRS and therefore inhibit Leu-mediated activation of 
mTORC1 (Han et al. 2012). Here, we show that leucinol is a potent inhibitor of 
Hcy-mediated effects on amino acid-mTORC1 signaling pathway. Of note, 
leucinol relocalized Flcn to the lysosomal membranes (Figure 3.14 A and B) and 
translocated TFEB to the nucleus as a possible consequence of mTORC1 
inhibition (Figure 4.8). We did further investigation to follow what leucinol 
implicated in autophagy pathway. As expected, leucinol inhibited mTORC1 
activity in presence of Hcy and induced autophagy which was detectable as a 
decrease in LC3I and increase in LC3II formation (Figure 4.10). However, in 
order to distinguish if the LC3II increase was due to lysosomal inhibition or high 
conversion rate from LC3I to LC3II, we included Chloroquine to inhibit lysosomal 
function and assessed the difference in LC3II formation. Data showed that LC3II 
accumulation in leucinol treatments combined with Chloroquine was higher 
compared to leucinol-treatment alone (Figure 4.11), which implicated that 
leucinol did not affect lysosomal function but increased autophagy flux. 
Furthermore, we observed a lower rate of proliferation in leucinol-treated 
cells compared to cells treated with nutrient-rich media without leucinol (Figure 
4.12 A). This effect could be due to inhibition of mTORC1 activity, although it 
needs further investigation to assess if leucinol interferes with cell proliferation. In 
order to exclude the possibility of mTORC2 inhibition by leucinol, the 
phosphorylated levels of AKT (S473) were assessed in cells treated with or 
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without leucinol. Data indicated no significant changes in protein levels of P-AKT 





Figure 4.10 Leucinol inhibits homocysteine-driven mTORC1 activity. HEK293T 
cells were treated with RPMI complete and starvation media with or without Hcy 
and leucinol. Leucinol inhibited mTORC1 activity in presence of Hcy as indicated 
by decreased level of phospho-P70/S6Kinase. This leucinol-related mTORC1 
inhibition was accompanied by an increase in LC3II protein levels. Bar graphs 
represent a quantitative analysis of protein levels assessed by immunoblot 























Figure 4.11 Leucinol increases autophagy flux. HEK293T cells were treated with 
RPMI complete and starvation media with or without Hcy/leucinol and 
Chloroquine. Chloroquine and leucinol co-treatments increased LC3II formation 
compared to leucinol treatment alone which represented leucinol as a component 
which increased autophagy induction and flux but had no lysosomal inhibitory 
effects. Bar graphs represent a quantitative analysis of protein levels assessed 












Figure 4.12- A and B Leucinol reduces cell proliferation without affecting 
mTORC2. A) HEK293T cells treated with leucinol showed a reduced rate of cell 
proliferation. Bar diagram represents the number of live cells in each treatment. 
B) P-AKT473 was assessed to measure mTORC2 activation upon leucinol 







Mechanistic target of rapamycin is known to modulate autophagy as autophagy 
modulators have been found to be the target of mTORC1 kinase activity (Kim et 
al. 2011; Martina et al. 2012). Here we demonstrated that Hcy-positive impact on 
mTORC1 activity impinges autophagy through phosphorylation of the two major 
autophagy-driving factors: ULK1 and TFEB. Hyperactive mTORC1 
phosphorylated ULK1 and consequently reduced LC3 lipidation. It also 
dampened TFEB-driven transcription of autophagy-related genes. We also 
showed leucinol to be a potent inhibitor of the negative Hcy-mediated effects on 
autophagy, thereby confirming that Hcy modulates mTORC1-TFEB pathway 













HOMOCYSTEINE IS NEUROTOXIC BY PROMOTING FORMATION OF 
ABNORMAL PROTEINS 
 
Since high levels of Hcy have been detected in sporadic AD patients (Zhuo, 
Wang, and Pratico 2011; Li, Chu, and Barrero 2014; Kamat et al. 2015; Coppedè 
2010) a need arose to elucidate the molecular mechanism behind the correlation 
between high plasma Hcy concentration and disease progression, which 
correlates with aging (Levine et al. 2008; Tucker et al. 2005). Notably, AD 
hallmarks including memory loss, the formation of the amyloid deposits, and 
phosphorylated tau neurofibrillary tangles, have been correlated with HHcy (Li et 
al. 2014), identifying Hcy particularly as a risk factor for AD (Morris 2003; 
Pacheco-quinto et al. 2006). The reason for the notion that Hcy is a risk factor for 
AD and not the disease marker, arises from the epidemiological studies on AD 
patients which demonstrated high concentration levels of Hcy in patients’ plasma 
prior to the development of dementia (Seshadri, 2006). Extensive research to 
elucidate pathways by which Hcy affects neurons is being carried out; some of 
which show that Hcy activates N-methyl-D-aspartate (NMDA) receptors (Lipton et 
al. 1997), oxidative stress (Perna, Ingrosso, and Santo 2003) and modification of 
DNA methylation (Fuso et al. 2005), all of which being detrimental contributions 
of Hcy to the brain. Additionally, Li et al. have proposed two independent 
pathways through which Hcy contributes to exacerbation of AD phenotype: 
activation of γ-secretase and CDK5 pathways which lead to the formation of β-
amyloid deposition and accumulation of tau insoluble form, respectively (Li et al. 
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2014). Yet, there is no evidence to show whether Hcy-mediated mTORC1 
activation and associated inhibition of autophagy lead to the formation of these 
specific protein deposits.  
 
5.1 Results 
5.1.1 Homocysteine Induces the Formation of Abnormal Proteins 
Associated with Alzheimer’s Disease 
 
To identify future drug targets, it is crucial to elucidate the mechanism of Hcy 
action in AD pathophysiology, including the formation of β-amyloid and 
hyperphosphorylated Tau (Li et al. 2014). Hippocampal sections of 𝐶𝑏𝑠−/− mice 
were assessed for paired helical filaments (PHF) of phospho-Tau which showed 
a significant increase compared to wild type littermates (Figure 5.1 A, B and C). 
Increase in phospho-Tau was associated with aggregated microtubule-
associated protein 2 (MAP2) in 𝐶𝑏𝑠−/− mice (Figure 5.1 A). Interestingly, 
phospho-Tau tangles partially co-localized with P62-positive autophagosomes 
indicating that the recognition of PHF phospho-Tau took place in 𝐶𝑏𝑠−/− brains 
(Figure 5.1 B). Next interesting feature observed for phospho-Tau, was the 
morphology as lined up along blood vessels in normal mice, while phospho-Tau 
spread out in Cbs deficient mice brain sections, which might be another 
implication for abnormal clearance in 𝐶𝑏𝑠−/− mice (Figure 5.1 C). Similarly, 
overall amount of intracellular β-amyloid increased by ≈2.24 fold in knockout mice 






















Figure 5.1- A, B and C Cbs knockout mouse brains show accumulation of 
abnormal proteins. A) Paired helical filament phospho-Tau levels increased in 
hippocampal areas of 𝐶𝑏𝑠−/− mice. Microtubule-associated protein 2 (MAP2) 
looked punctated and indicated with fewer number of neurons in 𝐶𝑏𝑠−/− samples 
(pTau: 2.8 +/- 0.2-fold, P < 0.005; degen. MAP2: 2.6 +/- 0.2-fold; P < 0.01). B) 
pTau and P62 (autophagosomal marker) co-localized in Cbs mutated samples 
while overall pTau protein level increased in 𝐶𝑏𝑠−/−  compare to control sections 
(p62/pTau colocalization: 0.88 +/- 0.2 in 𝐶𝑏𝑠−/− vs. 0.22 +/- 0.1 in controls; P = 
0.001). C) Cbs knockout hippocampi showed increased levels of β-amyloid as 
compared to littermate controls (2.24 +/- 0.15-fold; P < 0.01). Bar diagrams show 
statistical evaluation of immunostained sections. Data are means +/- SEM (n = 5 
mice per group). **P ≤ 0.01, and ***P ≤ 0.005.  
 
 
5.1.2 The Homocysteine-Driven Increase in the Level of β-Amyloid is 
Reversible by Inhibition of mTORC1 Activity or Induction of Autophagy 
 
Ho et al. previously showed that Hcy exacerbates β-amyloid neurotoxicity in 
neurodegenerative diseases such as AD by increasing β-amyloid-mediated 
calcium levels in the cytoplasm and induction of apoptosis (Ho et al. 2001). Later, 
a link between Hcy and β-amyloid production was made through modification of 
γ-secretase activity, one of the enzymes responsible for cleavage of amyloid 
precursor protein in process of β-amyloid production (Li et al. 2014). Further 
studies revealed that AD phenotypes are reversible by inhibition of mTORC1 with 
Rapamycin in mouse models of AD (Spilman et al. 2010). Here, we show that 
Hcy enhances β-amyloid protein level through induction of mTORC1 activity and 
inhibition of autophagy. The role of autophagy in the prevention of 
neurodegeneration has been demonstrated before, as autophagy-deficient mice 
showed behavioral abnormality due to loss of neurons in their cerebral and 
cerebellar cortices (Komatsu et al. 2006). Employing ELISA assays to detect β-
amyloid 42 versus 40 levels in cultured human neurons which were treated with 
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ascending concentrations of Hcy, we detected an increase in β-amyloid 42/40 
levels proportional to Hcy concentrations (Figure 5.2 A). Homocysteine-treated 
human neurons were exposed to the mTORC1 inhibitor Rapamycin (Sabers et 
al. 1995) or the autophagy-inducing peptide TAT-Beclin1 (Shoji-Kawata et al. 
2013) to assess the role of mTORC1 activity and autophagy in amyloid formation 
and survival, respectively. Our data indicated a prominent role of mTORC1 and 
autophagy in the regulation of β-amyloid levels; as mTORC1 inhibition or 
autophagy induction, both reduced the levels of β-amyloid42/40 in our 
quantitative analyses (Figure 5.2 B).    
  
5.1.3 Homocysteine is Detrimental to Human Neurons 
Autophagy has been identified to be necessary for the maintenance of neuronal 
homeostasis, as inhibition of autophagy led to neurodegeneration in Atg7 
deficient mice (Komatsu et al. 2006). Given that activation of mTORC1 
attenuates autophagy induction, we investigated the role of Hcy-mediated 
mTORC1 activity on the viability of human neurons. The viability of the cells was 
measured by employing viability assays detecting levels of cellular ATP. The 
viability of cultured human neurons exposed to Hcy dramatically decreased 
during the fourth days of treatment (Figure 5.3 A), while Rapamycin and TAT-






















Figure 5.2- A and B Homocysteine increases levels of intracellular amyloid in 
human neurons. A) Human neuroprogenitor cells were treated with increasing 
Hcy concentrations and subjected to ELISA assays. Cellular β-amyloid 42/40 
ratio increased proportionally to increasing levels of Hcy concentration (0.05 mM: 
1.9 +/- 0.2; 0.5 mM: 2.8 +/- 0.2). B) Rapamycin (mTORC1 inhibitor) and TAT-
Beclin1 (autophagy inducer peptide) decreased the ratio of β-amyloid 42/40 in 
HHcy conditions. Data are means +/- SEM (n = 5 independent experiments). *P ≤ 
































Figure 5.3- A and B Homocysteine proceeds degeneration of human neurons. 
Human neuroprogenitor cells were treated with Hcy for different periods of time 
and followed by luciferase-based viability assay measuring the levels of ATP. 
Hcy degenerated neurons drastically after four days (A), the phenotype which 
was rescued in Rapamycin and TAT-Beclin1 treatments (B). Data are means +/- 






5.1.4 Unfolded Protein Response is Upregulated in Cbs Deficient Mice 
Unfolded protein response (UPR) senses the accumulation of abnormal proteins 
and triggers, among other factors, phosphorylation of protein kinase RNA-like 
endoplasmic reticulum kinase (PERK) which was proposed to become activated 
through the Hcy-mediated pathway (Zhang et al. 2001). Upon PERK activation, 
eIF2α is phosphorylated and induces the production of ATF4 and 
CCAAT/enhancer-binding protein homologous protein (CHOP), a pro-apoptotic 
transcription factor (Babcock et al. 2013). Thereby we decided to assess the 
amount of CHOP protein level in our Cbs KO mouse brain sections. Mouse 
hippocampal sections showed increased formation of CHOP which was 




Formation of β-amyloid and phospho-Tau are considered as hallmarks of AD (Li 
et al. 2014). To evaluate neurotoxicity of Hcy, it was crucial to assess its 
contribution to the formation of the abnormal proteins. Here we demonstrated 
that Hcy indeed led to the formation of β-amyloid and phospho-Tau in 
hyperhomocysteinemic mouse brains. These mice had phospho-Tau tangles 
spread throughout the cells, while wild-type mice showed decreased levels of 
phospho-Tau along blood vessels in the brain. Accumulation of AD-specific 
protein deposits in HHcy mouse brains and decreased viability of human neurons 
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exposed to Hcy supports the notion that Hcy is likely a driver of AD 
pathophysiology. Additionally, we could rescue the phenotype by inhibition of 
mTORC1 or activation of autophagy. Our data underlined the importance of 
autophagy in neuronal homeostasis. However, future studies need to be 














Figure 5.4 Cbs knockout mice have higher CHOP levels and correlate with 
increase in activated astrocytes. CHOP staining increased in hippocampal 
sections of Cbs knockout mice which was in parallel with increase in GFAP 





DISCUSSION AND FUTURE DIRECTIONS 
 
It is noteworthy to elucidate how Hcy as a common disease risk factor 
contributes to disease pathogenesis. Homocysteine has been correlated with 
cardiovascular disease (Clarke et al. 1991) and neurodegeneration by induction 
of apoptosis in neurovascular cells (Kamat et al. 2015; Agnati et al. 2005). The 
pathway by which Hcy affects apoptosis is not fully understood. In this 
dissertation, we could shed light on one of the possible pathways through which 
Hcy is sensed in the cells and leads to the phenotype observed in 
neurodegenerative diseases. HEK293T cells and reprogrammed human neurons 
were utilized in the presented in-vitro studies while Cbs deficient mice 
represented the genetic model with high plasma Hcy concentration levels 
(≈300uM) (Choumenkovitch et al. 2002) to perform in-vivo studies.  
 
6.1 Homocysteine Increases mTORC1 Activity and Localization on 
Lysosomal Membrane 
 
The relevance of high mTORC1 activity in neurodegenerative diseases has been 
proposed in some studies (Rubinsztein 2006; Laplante and Sabatini 2012). 
Having that in mind we evaluated the mTORC1 activity of brain lysates obtained 
from AD and control patients. Our data revealed hyperactivation of mTORC1 in 
disease cases while the protein levels of mTORC1 activator (Rheb) and inhibitor 
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(TSC2) remained equal between the experimental groups (Figure 3.1 A, B, and 
C). Activation of mTORC1 has been related to various upstream signaling 
pathways among which growth factor and amino acid signaling represented the 
most crucial ones (Laplante and Sabatini 2012; Khayati et al. 2015). Growth 
factors are necessary to inhibit TSC2 deterrent activity toward Rheb (Tee et al. 
2003) & (Bar-Peled et al. 2013); whereas amino acids are main players of 
placing mTORC1 on lysosomal membrane where Rheb resides to activate 
mTORC1 (Reddy et al. 2016; Inoki et al. 2003; Zoncu 2011). Among amino 
acids, Leu has the strongest impact on mTORC1 activity, yet is insufficient to 
activate mTORC1 by its own (Bar-peled and Sabatini 2014). However, the 
influence of amino acid metabolites on mTORC1 activation have not been 
addressed yet. Here, we proposed that mTORC1 is capable of sensing Hcy to 
up-regulate its activity. Homocysteine-treated cells elevated mTORC1 activity in 
presence and absence of Leu (Figure 3.2 and 3.3 A, B and C). Likewise, we 
showed that Hcy is capable of inducing mTORC1 recruitment on the lysosomal 
membrane (Figures 3.10 A and B). Interestingly, our in-vivo studies in Cbs 
deficient mice resembled the phenotype seen in-vitro, in Hcy-treated cells. 
Microscopic evaluation in hippocampal regions of Cbs knockout and wild-type 
mice revealed an increase in overall levels of mTORC1 in Cbs deficient mice 
which co-localized at the lysosomal membrane. Interestingly, the number of 
LAMP2 positive organelles decreased which could be a likely consequence of 




6.2 Homocysteine-Driven mTORC1 Activity is Specific to Homocysteine 
Homocysteine-driven mTORC1 activity was assumed to be independent of AKT 
signaling pathways, as phosphorylation levels of AKT T308 and S473 did not 
change in Hcy-treated cells and Cbs deficient mouse brain lysates (Figure 3.4 
and 3.5 A and B). As such, AKT S473 phosphorylation levels were found to be 
the same in the analyzed post-mortem brain samples from AD and control 
patients (Figure 3.6). These data indicated that the growth factor signaling 
pathway and mTORC2 activity were not involved in Hcy-driven regulation of 
mTORC1 activity. Given that Hcy is unstable in cells and converts to Hcy-
thiolactone (Jakubowski 1999; Jakubowski 2015; Akchiche et al. 2016), we 
designed experiments to assess whether mTORC1 activity can be driven by Hcy-
thiolactone. We detected no significant changes in mTORC1 activity upon 
treatment of the cells with Hcy-thiolactone (Figure 3.7). In parallel, mTORC1 
activity was measured in mouse brain lysates deficient for Bleomycin and 
Paraoxonase1 enzyme activities. These mice had a high level of Hcy-thiolactone 
(Borowczyk et al. 2012) but showed no increased mTORC1 activity compared to 
control mice fed with Met (Figure 3.8). As Hcy-thiolactone is harshly reactive and 
able to bind to lysine residues of proteins, it is known to be detrimental to cells 
(Jakubowski 1999; Akchiche et al. 2016). However, our data eliminated the role 
of Hcy-thiolactone in activation of mTORC1.  
Moreover, we excluded the possibility of mTORC1 hyperactivation due to 
the accumulation of amino acids in the cytoplasm, which was the result of 
preclusion in protein synthesis, implicated by Hcy similar to cycloheximide. To 
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this end, we evaluated the impact of other amino acids such as cysteine on 
mTORC1 activity. Cysteine was the final product in process of Hcy conversion by 
CBS enzyme but did not exhibit a significant effect on mTORC1 activation 
implicating Hcy-driven mTORC1 activity being specific to Hcy (Figure 3.9). 
 
6.3 Homocysteine Induces mTORC1 Activity through Interaction with 
LeuRS-Folliculin Complex 
 
Molecular mechanisms through which Hcy affects mTORC1 activity were 
investigated in this dissertation. In addition to the regular role of LeuRS in 
process of protein translation (Park, Ewalt, and Kim 2005), its ability in binding to 
Hcy, although with lower affinity, in process of amino acid editing (Jakubowski 
2012), led us to assess the possible way through which LeuRS relays the signal 
to mTORC1 upon binding to Hcy. Since Flcn’s GAP activity on Rag C/D was 
investigated by Tsun et al. (Tsun et al. 2013), we assessed the possibility of 
LeuRS interaction with Flcn. To this end, immunoprecipitation analyses were 
performed and could prove the existence of such interaction between the two 
proteins; although LeuRs binding to Flcn turned out not to be dependent on the 
presence of amino acids in the culture media (Figure 3.12 A and B). Given that 
Flcn localization differed upon Leu availability (Petit et al. 2013; Tsun et al. 2013), 
Hcy impact on the localization of LeuRS-Flcn complex was assessed in this 
research project. Interestingly, our data showed that Hcy was able to diffuse Flcn 
in the cytoplasm while was resided on the lysosomal membrane in contact with 
Rags in absence of Leu or Hcy (Figure 3.13, 3.14 A and B). Of note, Hcy impact 
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on Flcn localization was hampered by employing leucinol, a Leu derivative that 
inhibited LeuRS activity (Han et al. 2012), suggesting a mediating role for LeuRS 
to activate Flcn in presence of Hcy. Further analysis needs to be conducted to 
investigate the mechanism through which LeuRS relays the signal to Flcn.  
Another possible factor which could be functional in sensing Leu is 
Sestrin2. Sestrin2 was proposed to preclude GATOR2-GATOR1 interaction in 
absence of amino acids, releasing GATOR1 to act as a GAP, therefore an 
inhibitor for Rag A/B; whereas, Leu binding to Sestrin2 perturbed its interaction 
with GATOR2 and rendered Rag A/B active (Wolfson et al. 2016). Sestrin2 
contribution to Hcy-mediated mTORC1 activation was assessed by evaluating 
Sestrin2 protein levels in Hcy-treated cells. There existed evidence 
demonstrating that prolonged amino acid deprivation promoted Sestrin2 
transcription in an ATF4-dependent manner (Ye et al. 2015). Our data suggested 
that Sestrin2 protein levels did not change in presence of Hcy, (Figure 3.15 A 
and B) indicating first, Hcy was potent in precluding the starvation phenotype-
related upregulation of Sestrin2, and second, there was no plausible induction of 
Sestrin2 production caused by Hcy.  
 
6.4 Homocysteine Inhibits Autophagy Induction  
through Dampening TFEB Activity 
 
Impairment of autophagy in AD patients has been considered with the 
observation of enlarged double membranous organelles, resembling 
autophagosomes (Levine et al. 2008; Nixon and Yang 2011). This phenotype is 
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correlated with the notion that proteinopathies arise from the accumulation of 
protein aggregates in the cytoplasm of neurons observed in most of the human 
neuronal pathologies such as AD, Parkinson’s and Huntington’s diseases 
(Williams et al. 2006). Given that autophagy can be under the control of 
mTORC1 activity through ULK1 (Kim et al. 2011) and TFEB phosphorylation 
(Martina et al. 2012; Roczniak-Ferguson et al. 2012), we investigated the impact 
of Hcy on autophagy. Our data obtained from autophagy flux assays revealed a 
role for Hcy in an increase of phospho-ULK1 which impacted LC3 lipidation 
(Figure 4.3). Taking these data into consideration, we concluded that Hcy 
inhibited autophagy induction that correlated with decreased formation of LC3-
positive autophagosomes (Figure 4.1). Given that Torin reversed Hcy-mediated 
phenotype by increasing the number of LC3 punctual staining, we proved that 
Hcy effect on autophagy was mediated through the activation of mTORC1 
(Figure 4.1). 
Tandem fluorescent-tagged LC3 (ptf-LC3), a conjugated form of LC3 with 
GFP and mRFP fluorescent proteins, was utilized as a marker to distinguish 
autophagosomes before and after fusion with lysosomes, the final destination of 
autophagic organelles (Kimura, Noda, and Yoshimori 2007). Using this construct, 
we could confirm that Hcy inhibited LC3 lipidation and autophagosomal 
maturation, as indicated respectively by a reduction in the number of both green 
and red organelles (Figure 4.4). 
The data we obtained in autophagy assays were based on short Hcy-
treatments of the cells. However, since HHcy has been correlated with AD 
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(Coppedè 2010), it is important to assess effects of chronic exposure to high Hcy 
levels. Thus, we examined the rate of autophagy induction in cells exposed to 
Hcy, overnight. Interestingly, LC3I & II decreased in the long-term exposure of 
cells to Hcy (Figure 4.5), thus led us to look at the activity of the upstream 
effector of autophagy induction, TFEB. It is important to note that LC3I levels 
were indirect reporters of TFEB-mediated transcriptional activity (Karim, 
Kawanago, and Kadowaki 2014). Similarly, reduction in protein levels of LC3 and 
p62, also a TFEB-target gene (Sahani, Itakura, and Mizushima 2014), were 
observed in hyperhomocysteinemic mice brain samples (Figure 4.6). The data 
were corroborated by measuring the activity of TFEB, employing a 4xCLEAR-
luciferase construct, an established reporter for TFEB activity (Sardiello et al. 
2009). Cells treated with Hcy or Leu overnight showed a reduction in TFEB 
activity (Figure 4.7 A). These data were also confirmed by conducting 
experiments that showed cytoplasmic localization of TFEB in Hcy-treated cells or 
hyperhomocysteinemic mouse brain samples (Figures 4.8 & 4.9) where we 
expect to find TFEB while mTORC1 is active (Martina et al. 2012).  
 
6.5 Elevation in Levels of Abnormal Proteins Correlates  
with Cellular Homocysteine Levels  
 
The relevance of high levels of Hcy in plasma and the brain (HHcy) in the 
progression of AD has been discussed in the field. First, from the possibility of 
Hcy conversion to Hcy-thiolactone, it has been correlated with the pathology of 
the disease and production of β-amyloid (Borowczyk et al. 2012). Additionally, 
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Borowczyk et al. and Suszynska et al. have proposed Hcy-thiolactone as a 
neurotoxic agent whose phenotype was ameliorated by Bleomycin hydrolase 
(Borowczyk et al. 2012; Suszynska et al. 2010). Second, Hcy was able to 
damage vascular integrity, a phenotype which altered angiogenesis and 
increased membrane permeability; both of which have been observed in AD 
pathogenesis (Kamat et al. 2015). Li et al. also lent further support to the 
hypothesis that Hcy exacerbates AD phenotype; the authors introduced 
mechanisms by which Hcy led to the formation of β-amyloid and phospho-Tau by 
induction of γ-secretase and CDK5 activities, respectively (Li et al. 2014). An 
alternative pathway through which Hcy metabolism leads to formation of β-
amyloid was discussed by Fuso et al. They showed that reduction of S-
adenosine methionine (SAM) in cells deficient from enzymes converting Hcy to 
Met (methionine synthase), led to hypomethylation and upregulation of BACE 
and PS1 genes; the result is production of more β-amyloid (Fuso et al. 2005). 
Interestingly, what we proposed here was unique since was attributed to Hcy 
influence on the production of AD-related phenotype through modulation of 
mTORC1 activity. The increase in β-amyloid 42, the aggregation-prone form of β-
amyloid, due to Hcy-treatments were reversed to a normal level by applying 
Rapamycin and TAT-Beclin1 (Figure 5.2 A and B); both of which modulated the 
mTORC1-autophagy pathway. Of note, our data supported Fuso et al. 
hypothesis regarding upregulation of genes related to production of β-amyloid, 
since mTOR is the master regulator of protein synthesis. We could also detect an 
increase of both β-amyloid and phospho-Tau in Cbs knockout mice (Figure 5.1 A, 
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B and C). Interestingly, the same phenotype was observed in TFEB-deficient 
mice (Reddy et al. 2016), unraveled the role of TFEB in the pathway. 
 Thus, Hcy not only inhibits clearance of protein aggregates through 
modulation of TFEB activity, but also increases the production of aggregation-
prone β-amyloid. 
  
6.6 Homocysteine Contributions to Cell Death 
Homocysteine contributions to the cell death in AD has been related to induction 
of cerebral microangiopathy, endothelial dysfunction, oxidative stress, 
neurotoxicity and apoptosis (Kamat et al. 2015), while neuroinflammation has 
been observed prior to neuronal loss. (Walker and Sills 2012). Homocysteine 
oxidation due to its sulfur group has been shown in the cytoplasm and culture 
media. Oxidation of Hcy led to the formation of reactive oxygen species (ROS) 
causing neuroinflammation, apoptosis (Yan et al. 2006) and cerebrovascular 
dysfunction (Ataie, Sabetkasaei, and Haghparast 2010; Kamat et al. 2015). 
Alternatively, Hcy contribution in disruption of blood-brain barrier has been 
correlated with an increase of matrix metalloproteinase enzyme activity and 
expression observed concomitantly in Cbs deficient mice (Tyagi et al. 2012). Our 
viability assays revealed a role for the mTORC1-autophagy pathway in Hcy-
driven cell death; since mTORC1 inhibition and autophagy induction could 




Given that neurodegeneration was triggered by Hcy, further research 
needs to be implicated to decipher the mechanism of Hcy-triggered cell death. A 
few possibilities have been proposed earlier; such as induction of oxidative stress 
(Yan et al. 2006), deterioration of mitochondrial function by Hcy which led to 
apoptosis (Kronenberg et al. 2009), and activation of matrix metalloproteinase 
enzymes that perturbed extracellular matrix leading to blood-brain barrier 
malfunction (Rhodehouse et al. 2013). Similarly, the role of β-amyloid peptide 
aggregation in neuroinflammation, DNA damage, and neuronal cell death has 
been evaluated (Kamat et al. 2015; Kruman et al. 2002). Yet, there is no 
evidence showing the relevance of Hcy-mediated mTORC1-autophagy pathway 
in the procedure of cell death induction. 
Given the results presented in this dissertation project, it is noteworthy to 
consider the contribution of mTORC1 hyperactivity to cell death. An accumulating 
body of evidence supported the notion that mTORC1 inhibition favors longer life 
span (Lushchak et al. 2017). mTORC1 hyperactivity increased the load of mRNA 
translation leading to enhanced protein production which could lead to the 
formation of toxic aggregations in the cell; thus, down-regulation of ribosomal S6 
kinase has been shown to attenuate aging process, effectively (Selman et al. 
2009). The notion that proteasomal degradation was also dampened upon 
mTORC1 activation by decreasing overall protein ubiquitylation (Zhao et al. 
2015) and proteasomal chaperones (Rousseau and Bertolotti 2016), gives 
support to the hypothesis that chronic mTORC1 activation is detrimental for cells.  
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Moreover, the contribution of mTORC1 activity to cell death could be 
mediated by chronic attenuation/insufficiency of autophagic clearance; the 
pathway which plays a crucial role in the maintenance of neuronal homeostasis 
(Rubinsztein 2006; Yue et al. 2009). Other than being an active process of eating 
redundant proteins and old organelles, autophagy interacts with other signal 
transduction pathways in the cell. For example, the crosstalk between autophagy 
and apoptosis is implemented by Beclin1/Bcl2 interaction. While Beclin1 is 
essential for initiation and elongation of autophagosomes (Glick et al. 2010; 
Liang et al. 2006), Bcl2 inhibits such function. The interaction between Beclin1 
and Bcl-2 depends upon multiple factors in the cell such as their expression 
level, phosphorylation level and localization where they interact (Marquez and Xu 
2012). The alternative interplay of autophagy and apoptosis is given by the pro-
apoptotic function of cleaved Beclin1. Following cleavage, a C-terminal fragment 
of Beclin1 enters mitochondria to release pro-apoptotic factors in nutrient-poor 
conditions (Wirawan et al. 2010).  
Our data indicate that Hcy-mediated cell death requires 4 days (Figure 5.3 
A). However, activation of NMDA receptors occurs quickly (Lipton et al. 1997), 
whereas Hcy-mediated mTORC1 activation followed by inhibition of autophagy 
requires more time to disturb neuronal homeostasis leading to cell death. Similar 
observation has been made in Atg7 knockout animals which occurs after 28 
weeks of birth (Komatsu et al. 2006), suggesting that not neuronal differentiation 
or other developmental processes in the brain are disturbed by autophagy 
inhibition but the neuronal homeostasis. 
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6.7 Future Directions 
Having all these cell death-promoted pathways in mind, there is an alternative 
pathway which was also proposed to be triggered in presence of Hcy, the 
unfolded protein response (UPR) (Zhang et al. 2001). Our data showed that 
CHOP staining is upregulated in Cbs deficient mice which correlates with higher 
GFAP staining (Figure 5.4). Future studies need to be done to decipher what cell 
types specifically express CHOP. Here we showed that inflammation was 
triggered in dentate gyrus of Cbs knockout mice represented by an increase in 
activated astrocytes (Figure 5.4). We speculate that loss of MAP2 signaling in 
Cbs deficient hippocampi (Figure 5.1 A) is due to induction of inflammatory 
response. Our future studies will shed light on the way through which Hcy 
initiates inflammation in-vitro and in-vivo. We are planning to do Multiplex assays 
in Hcy-treated neurons. Likewise, we will treat methionine-fed mice with Torin to 
inhibit mTOR activity and correlate with levels of activated astrocytes (GFAP 
staining). We assume that Hcy-mediated mTORC1/autophagy modulation 
increases protein accumulation in two ways: by increasing protein synthesis and 
decreasing the autophagic clearance of protein aggregates and other cellular 








Taken together, data presented in this dissertation show that Hcy upregulates 
mTORC1 activity, inhibits autophagic clearance eventually leading to the 
formation of pathogenic protein aggregates. The mechanisms delineated in this 
work may help developing novel approaches that target components of the 
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